{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":null,"value":72},{"name":null,"value":26},{"name":null,"value":40},{"name":null,"value":27},{"name":null,"value":80},{"name":null,"value":28},{"name":null,"value":35},{"name":null,"value":10},{"name":null,"value":134},{"name":null,"value":121},{"name":null,"value":78},{"name":null,"value":29},{"name":null,"value":32},{"name":null,"value":31},{"name":null,"value":33},{"name":null,"value":126},{"name":null,"value":36},{"name":null,"value":82},{"name":null,"value":37},{"name":null,"value":115},{"name":"Government Matters","value":"cg-2"},{"name":null,"value":1},{"name":null,"value":6},{"name":null,"value":71},{"name":null,"value":21},{"name":null,"value":23},{"name":null,"value":116},{"name":null,"value":24},{"name":null,"value":135},{"name":null,"value":25},{"name":null,"value":110},{"name":null,"value":20},{"name":null,"value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":null,"value":129},{"name":null,"value":2},{"name":null,"value":38},{"name":null,"value":3},{"name":null,"value":5},{"name":null,"value":19},{"name":null,"value":7},{"name":null,"value":4},{"name":null,"value":136},{"name":null,"value":13},{"name":null,"value":14},{"name":null,"value":15},{"name":null,"value":17},{"name":null,"value":18},{"name":null,"value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":null,"value":133},{"name":null,"value":106},{"name":null,"value":124},{"name":null,"value":111},{"name":null,"value":132},{"name":null,"value":131},{"name":null,"value":102},{"name":null,"value":125},{"name":null,"value":127},{"name":null,"value":107},{"name":null,"value":112},{"name":null,"value":105},{"name":null,"value":109},{"name":null,"value":103},{"name":null,"value":128},{"name":null,"value":123},{"name":null,"value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"cg-2","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"K","per_page":12,"people":[{"id":443946,"version":1,"owner_type":"Person","owner_id":6689,"payload":{"bio":"\u003cp\u003eBarry Kamar draws on his background as a federal prosecutor and investment banker to represent global companies in government investigations and complex commercial litigation. He focuses his practice on representing companies, boards and individuals on a wide range of criminal, regulatory and civil matters, including matters involving the U.S. Department of Justice, the U.S. Securities and Exchange Commission and other domestic and international regulatory agencies, as well as on civil matters involving high stakes business disputes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eA skilled trial lawyer, Barry is often called upon for his courtroom advocacy and business-minded approach. He served for over a decade at DOJ and the SEC where he held various senior positions including Chief of the Public Protection Unit at the U.S. Attorney\u0026rsquo;s Office for the District of New Jersey and Senior Counsel at the SEC\u0026rsquo;s New York office. In these roles, Barry oversaw significant public investigations and prosecutions involving financial fraud and federal securities law violations, spending much of his time conducting jury trials in federal court.\u003c/p\u003e\n\u003cp\u003ePrior to his government service, Barry was a litigator at Paul Weiss in New York, where he successfully defended financial services, pharmaceutical and media clients in multi-million dollar securities, antitrust and FCPA matters, as well as in commercial disputes involving cutting-edge legal issues.\u003c/p\u003e\n\u003cp\u003eBarry also is a former investment banker at Morgan Stanley \u0026amp; Co. and former economist at PricewaterhouseCoopers, where he advised energy, construction and technology clients on a\u0026nbsp;variety of strategic corporate transactions, including mergers, acquisitions, corporate financing and transfer pricing.\u003c/p\u003e\n\u003cp\u003eA native Arabic speaker, Barry lived for more than 17 years in the Middle East, including Cairo, Egypt, Muscat, Oman and Abu Dhabi, UAE. Barry also lived for several years in Mexico City, Mexico, and is proficient in Spanish.\u003c/p\u003e","slug":"barry-kamar","email":"bkamar@kslaw.com ","phone":null,"matters":["\u003cp\u003eProject44, Inc. v. MyCarrier, LLC: represent SaaS freight logistics provider in commercial dispute\u003c/p\u003e","\u003cp\u003eSkillz Platform, Inc. v. Papaya Gaming, Ltd., No. 24-1646 (S.D.N.Y.): represent online gaming platform in Lanham Act false advertising matter against competitor\u003c/p\u003e","\u003cp\u003eAdvise multinational life sciences company in connection with internal investigation\u003c/p\u003e","\u003cp\u003eRepresent national financial services company in DOJ investigation\u003c/p\u003e","\u003cp\u003eRepresent multinational OEM in SEC FCPA matter\u003c/p\u003e","\u003cp\u003eRepresent multinational semiconductor manufacturer in DOJ and SEC inquiries regarding export controls\u003c/p\u003e","\u003cp\u003eIRA Financial Trust v. Gemini Trust, LLC, 22-cv-4672 (S.D.N.Y.): Bet-the-company litigation concerning data breach and theft of cryptocurrency.\u003c/p\u003e","\u003cp\u003eerinMedia, LLC v. Nielsen Media Research, Inc., 05-cv-1123 (M.D. Fla.): Antitrust matter involving television media ratings.\u003c/p\u003e","\u003cp\u003eRetractable Technologies, Inc. v. Becton Dickinson \u0026amp; Co., 01-cv-36 (E.D. Tex.): Antitrust matter involving medical devices.\u003c/p\u003e","\u003cp\u003eRepresentation of multi-national corporation in connection with a DOJ FCPA investigation of a Latin American subsidiary\u0026rsquo;s conduct.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":1,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":2,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":3,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":4,"source":"capabilities"},{"id":25,"guid":"25.capabilities","index":5,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":6,"source":"capabilities"},{"id":699,"guid":"699.smart_tags","index":7,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":8,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":9,"source":"smartTags"},{"id":1434,"guid":"1434.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"Kamar","nick_name":"Barry","clerkships":[],"first_name":"Barry","title_rank":9999,"updated_by":202,"law_schools":[{"id":2055,"meta":{"degree":"J.D.","honors":"honors","is_law_school":"1","graduation_date":"2006-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"The Best Lawyers in America ","detail":"2024 "}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eBarry Kamar draws on his background as a federal prosecutor and investment banker to represent global companies in government investigations and complex commercial litigation. He focuses his practice on representing companies, boards and individuals on a wide range of criminal, regulatory and civil matters, including matters involving the U.S. Department of Justice, the U.S. Securities and Exchange Commission and other domestic and international regulatory agencies, as well as on civil matters involving high stakes business disputes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eA skilled trial lawyer, Barry is often called upon for his courtroom advocacy and business-minded approach. He served for over a decade at DOJ and the SEC where he held various senior positions including Chief of the Public Protection Unit at the U.S. Attorney\u0026rsquo;s Office for the District of New Jersey and Senior Counsel at the SEC\u0026rsquo;s New York office. In these roles, Barry oversaw significant public investigations and prosecutions involving financial fraud and federal securities law violations, spending much of his time conducting jury trials in federal court.\u003c/p\u003e\n\u003cp\u003ePrior to his government service, Barry was a litigator at Paul Weiss in New York, where he successfully defended financial services, pharmaceutical and media clients in multi-million dollar securities, antitrust and FCPA matters, as well as in commercial disputes involving cutting-edge legal issues.\u003c/p\u003e\n\u003cp\u003eBarry also is a former investment banker at Morgan Stanley \u0026amp; Co. and former economist at PricewaterhouseCoopers, where he advised energy, construction and technology clients on a\u0026nbsp;variety of strategic corporate transactions, including mergers, acquisitions, corporate financing and transfer pricing.\u003c/p\u003e\n\u003cp\u003eA native Arabic speaker, Barry lived for more than 17 years in the Middle East, including Cairo, Egypt, Muscat, Oman and Abu Dhabi, UAE. Barry also lived for several years in Mexico City, Mexico, and is proficient in Spanish.\u003c/p\u003e","matters":["\u003cp\u003eProject44, Inc. v. MyCarrier, LLC: represent SaaS freight logistics provider in commercial dispute\u003c/p\u003e","\u003cp\u003eSkillz Platform, Inc. v. Papaya Gaming, Ltd., No. 24-1646 (S.D.N.Y.): represent online gaming platform in Lanham Act false advertising matter against competitor\u003c/p\u003e","\u003cp\u003eAdvise multinational life sciences company in connection with internal investigation\u003c/p\u003e","\u003cp\u003eRepresent national financial services company in DOJ investigation\u003c/p\u003e","\u003cp\u003eRepresent multinational OEM in SEC FCPA matter\u003c/p\u003e","\u003cp\u003eRepresent multinational semiconductor manufacturer in DOJ and SEC inquiries regarding export controls\u003c/p\u003e","\u003cp\u003eIRA Financial Trust v. Gemini Trust, LLC, 22-cv-4672 (S.D.N.Y.): Bet-the-company litigation concerning data breach and theft of cryptocurrency.\u003c/p\u003e","\u003cp\u003eerinMedia, LLC v. Nielsen Media Research, Inc., 05-cv-1123 (M.D. Fla.): Antitrust matter involving television media ratings.\u003c/p\u003e","\u003cp\u003eRetractable Technologies, Inc. v. Becton Dickinson \u0026amp; Co., 01-cv-36 (E.D. Tex.): Antitrust matter involving medical devices.\u003c/p\u003e","\u003cp\u003eRepresentation of multi-national corporation in connection with a DOJ FCPA investigation of a Latin American subsidiary\u0026rsquo;s conduct.\u003c/p\u003e"],"recognitions":[{"title":"The Best Lawyers in America ","detail":"2024 "}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11683}]},"capability_group_id":2},"created_at":"2025-12-05T05:01:45.000Z","updated_at":"2025-12-05T05:01:45.000Z","searchable_text":"Kamar{{ FIELD }}{:title=\u0026gt;\"The Best Lawyers in America \", :detail=\u0026gt;\"2024 \"}{{ FIELD }}Project44, Inc. v. MyCarrier, LLC: represent SaaS freight logistics provider in commercial dispute{{ FIELD }}Skillz Platform, Inc. v. Papaya Gaming, Ltd., No. 24-1646 (S.D.N.Y.): represent online gaming platform in Lanham Act false advertising matter against competitor{{ FIELD }}Advise multinational life sciences company in connection with internal investigation{{ FIELD }}Represent national financial services company in DOJ investigation{{ FIELD }}Represent multinational OEM in SEC FCPA matter{{ FIELD }}Represent multinational semiconductor manufacturer in DOJ and SEC inquiries regarding export controls{{ FIELD }}IRA Financial Trust v. Gemini Trust, LLC, 22-cv-4672 (S.D.N.Y.): Bet-the-company litigation concerning data breach and theft of cryptocurrency.{{ FIELD }}erinMedia, LLC v. Nielsen Media Research, Inc., 05-cv-1123 (M.D. Fla.): Antitrust matter involving television media ratings.{{ FIELD }}Retractable Technologies, Inc. v. Becton Dickinson \u0026amp; Co., 01-cv-36 (E.D. Tex.): Antitrust matter involving medical devices.{{ FIELD }}Representation of multi-national corporation in connection with a DOJ FCPA investigation of a Latin American subsidiary’s conduct.{{ FIELD }}Barry Kamar draws on his background as a federal prosecutor and investment banker to represent global companies in government investigations and complex commercial litigation. He focuses his practice on representing companies, boards and individuals on a wide range of criminal, regulatory and civil matters, including matters involving the U.S. Department of Justice, the U.S. Securities and Exchange Commission and other domestic and international regulatory agencies, as well as on civil matters involving high stakes business disputes.\nA skilled trial lawyer, Barry is often called upon for his courtroom advocacy and business-minded approach. He served for over a decade at DOJ and the SEC where he held various senior positions including Chief of the Public Protection Unit at the U.S. Attorney’s Office for the District of New Jersey and Senior Counsel at the SEC’s New York office. In these roles, Barry oversaw significant public investigations and prosecutions involving financial fraud and federal securities law violations, spending much of his time conducting jury trials in federal court.\nPrior to his government service, Barry was a litigator at Paul Weiss in New York, where he successfully defended financial services, pharmaceutical and media clients in multi-million dollar securities, antitrust and FCPA matters, as well as in commercial disputes involving cutting-edge legal issues.\nBarry also is a former investment banker at Morgan Stanley \u0026amp; Co. and former economist at PricewaterhouseCoopers, where he advised energy, construction and technology clients on a variety of strategic corporate transactions, including mergers, acquisitions, corporate financing and transfer pricing.\nA native Arabic speaker, Barry lived for more than 17 years in the Middle East, including Cairo, Egypt, Muscat, Oman and Abu Dhabi, UAE. Barry also lived for several years in Mexico City, Mexico, and is proficient in Spanish. Partner The Best Lawyers in America  2024  University of Texas  The University of Texas at Austin The University of Texas School of Law U.S. Court of Appeals for the Second Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York U.S. District Court for the Middle District of Florida U.S. District Court for the Northern District of Florida U.S. District Court for the Southern District of Florida Florida New York Federal Bar Association Vice-Chair, Federal Committee, Miami-Dade Bar Association Trial Lawyers, Criminal Law, and Business Law Sections, The Florida Bar Economic Club of Miami Project44, Inc. v. MyCarrier, LLC: represent SaaS freight logistics provider in commercial dispute Skillz Platform, Inc. v. Papaya Gaming, Ltd., No. 24-1646 (S.D.N.Y.): represent online gaming platform in Lanham Act false advertising matter against competitor Advise multinational life sciences company in connection with internal investigation Represent national financial services company in DOJ investigation Represent multinational OEM in SEC FCPA matter Represent multinational semiconductor manufacturer in DOJ and SEC inquiries regarding export controls IRA Financial Trust v. Gemini Trust, LLC, 22-cv-4672 (S.D.N.Y.): Bet-the-company litigation concerning data breach and theft of cryptocurrency. erinMedia, LLC v. Nielsen Media Research, Inc., 05-cv-1123 (M.D. Fla.): Antitrust matter involving television media ratings. Retractable Technologies, Inc. v. Becton Dickinson \u0026amp; Co., 01-cv-36 (E.D. Tex.): Antitrust matter involving medical devices. Representation of multi-national corporation in connection with a DOJ FCPA investigation of a Latin American subsidiary’s conduct.","searchable_name":"Barry Kamar","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":427592,"version":1,"owner_type":"Person","owner_id":832,"payload":{"bio":"\u003cp\u003eRob Keenan focuses on healthcare regulatory, transactional, and contracting matters. A partner in both our Healthcare practice and Data Security and Privacy practices, Rob represents health industry clients with respect to a broad range of issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRob advises health systems, hospitals, academic medical centers, clinical laboratories, home health and hospice providers, pharmacy benefit managers, and physician groups on a wide range of federal and state regulatory matters, with a particular focus on health information privacy and security as well as healthcare fraud and abuse laws, including the federal Anti-Kickback Statute and the Stark Law.\u003c/p\u003e\n\u003cp\u003eRob also advises hospitals, health systems, academic medical centers and large physician groups concerning regulatory and structuring issues related to physician contracting, including practice acquisitions, professional services arrangements and evolving value-based arrangements. Rob regularly assists clients with the design of Stark Law-compliant physician compensation methodologies, including within group practices. Rob has considerable experience troubleshooting existing arrangements, often finding compliant pathways, and has filed a number Stark Law voluntary disclosures with the Centers for Medicare \u0026amp; Medicaid Services when a Stark-compliant pathway could not be identified.\u003c/p\u003e\n\u003cp\u003eRob represents health industry clients in transactional matters, including performing healthcare regulatory due diligence in connection with mergers and acquisitions. Rob also advises clinical laboratories regarding CLIA and state law compliance, including in the context of sanction proceedings before the Centers for Medicare \u0026amp; Medicaid Services.\u003c/p\u003e\n\u003cp\u003eRob advises clients on federal and state health information privacy issues and has significant experience representing HIPAA covered entities and business associates, as well as medical device and pharmaceutical companies that encounter HIPAA-related issues. He provides advice regarding covered entity and business associate regulated status, proactive compliance, data use and sharing, incident response and breach reporting, de-identification, and clinical research issues.\u003c/p\u003e\n\u003cp\u003eRob regularly assists clients with managed care contracting issues, including contract review and negotiation; development of template language; and evaluation of regulated content, including applicability of federal law and state insurance codes. Rob served as the Editor of the American Health Law Association\u0026rsquo;s \u003cem\u003eHealth Plans Contracting Handbook\u003c/em\u003e, 7th ed. (2015), and served as Co-Editor of the 5th and 6th editions. Rob also spent time in-house at a national health insurance company advising managed care organization clients on various contracting and regulatory issues before returning to King \u0026amp; Spalding.\u003c/p\u003e\n\u003cp\u003eA regular speaker and writer, Rob is ranked as Band 1 for Healthcare in Georgia in Chambers USA Client's Guide to America's Leading Lawyers for Business and also is recognized in recent editions of The Best Lawyers in America and Expert Guides Best of the Best USA. He is a member of the American Health Law Association, the Health Law Section of the American Bar Association, and the State Bar of Georgia, and is a member and past President of the Georgia Academy of Healthcare Attorneys.\u0026nbsp;Rob was named \u0026ldquo;Lawyer of the Year\u0026rdquo; for Health Care Law in the 2023 Georgia edition of Best Lawyers.\u003c/p\u003e","slug":"robert-keenan","email":"rkeenan@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":115}]},"expertise":[{"id":6,"guid":"6.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":3,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":4,"source":"capabilities"},{"id":33,"guid":"33.capabilities","index":5,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":6,"source":"smartTags"},{"id":122,"guid":"122.capabilities","index":7,"source":"capabilities"},{"id":1202,"guid":"1202.smart_tags","index":8,"source":"smartTags"},{"id":107,"guid":"107.capabilities","index":9,"source":"capabilities"},{"id":740,"guid":"740.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"Keenan","nick_name":"Rob","clerkships":[],"first_name":"Robert","title_rank":9999,"updated_by":35,"law_schools":[],"middle_name":"M.","name_suffix":"III","recognitions":[{"title":"\"Rob provides excellent and practical guidance on complex HIPAA topics.\"","detail":"Chambers USA, 2022"},{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Georgia, 2005-2024"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eRob Keenan focuses on healthcare regulatory, transactional, and contracting matters. A partner in both our Healthcare practice and Data Security and Privacy practices, Rob represents health industry clients with respect to a broad range of issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRob advises health systems, hospitals, academic medical centers, clinical laboratories, home health and hospice providers, pharmacy benefit managers, and physician groups on a wide range of federal and state regulatory matters, with a particular focus on health information privacy and security as well as healthcare fraud and abuse laws, including the federal Anti-Kickback Statute and the Stark Law.\u003c/p\u003e\n\u003cp\u003eRob also advises hospitals, health systems, academic medical centers and large physician groups concerning regulatory and structuring issues related to physician contracting, including practice acquisitions, professional services arrangements and evolving value-based arrangements. Rob regularly assists clients with the design of Stark Law-compliant physician compensation methodologies, including within group practices. Rob has considerable experience troubleshooting existing arrangements, often finding compliant pathways, and has filed a number Stark Law voluntary disclosures with the Centers for Medicare \u0026amp; Medicaid Services when a Stark-compliant pathway could not be identified.\u003c/p\u003e\n\u003cp\u003eRob represents health industry clients in transactional matters, including performing healthcare regulatory due diligence in connection with mergers and acquisitions. Rob also advises clinical laboratories regarding CLIA and state law compliance, including in the context of sanction proceedings before the Centers for Medicare \u0026amp; Medicaid Services.\u003c/p\u003e\n\u003cp\u003eRob advises clients on federal and state health information privacy issues and has significant experience representing HIPAA covered entities and business associates, as well as medical device and pharmaceutical companies that encounter HIPAA-related issues. He provides advice regarding covered entity and business associate regulated status, proactive compliance, data use and sharing, incident response and breach reporting, de-identification, and clinical research issues.\u003c/p\u003e\n\u003cp\u003eRob regularly assists clients with managed care contracting issues, including contract review and negotiation; development of template language; and evaluation of regulated content, including applicability of federal law and state insurance codes. Rob served as the Editor of the American Health Law Association\u0026rsquo;s \u003cem\u003eHealth Plans Contracting Handbook\u003c/em\u003e, 7th ed. (2015), and served as Co-Editor of the 5th and 6th editions. Rob also spent time in-house at a national health insurance company advising managed care organization clients on various contracting and regulatory issues before returning to King \u0026amp; Spalding.\u003c/p\u003e\n\u003cp\u003eA regular speaker and writer, Rob is ranked as Band 1 for Healthcare in Georgia in Chambers USA Client's Guide to America's Leading Lawyers for Business and also is recognized in recent editions of The Best Lawyers in America and Expert Guides Best of the Best USA. He is a member of the American Health Law Association, the Health Law Section of the American Bar Association, and the State Bar of Georgia, and is a member and past President of the Georgia Academy of Healthcare Attorneys.\u0026nbsp;Rob was named \u0026ldquo;Lawyer of the Year\u0026rdquo; for Health Care Law in the 2023 Georgia edition of Best Lawyers.\u003c/p\u003e","recognitions":[{"title":"\"Rob provides excellent and practical guidance on complex HIPAA topics.\"","detail":"Chambers USA, 2022"},{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Georgia, 2005-2024"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4242}]},"capability_group_id":2},"created_at":"2025-05-26T05:02:31.000Z","updated_at":"2025-05-26T05:02:31.000Z","searchable_text":"Keenan{{ FIELD }}{:title=\u0026gt;\"\\\"Rob provides excellent and practical guidance on complex HIPAA topics.\\\"\", :detail=\u0026gt;\"Chambers USA, 2022\"}{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, Healthcare\", :detail=\u0026gt;\"Chambers USA, Georgia, 2005-2024\"}{{ FIELD }}Rob Keenan focuses on healthcare regulatory, transactional, and contracting matters. A partner in both our Healthcare practice and Data Security and Privacy practices, Rob represents health industry clients with respect to a broad range of issues.\nRob advises health systems, hospitals, academic medical centers, clinical laboratories, home health and hospice providers, pharmacy benefit managers, and physician groups on a wide range of federal and state regulatory matters, with a particular focus on health information privacy and security as well as healthcare fraud and abuse laws, including the federal Anti-Kickback Statute and the Stark Law.\nRob also advises hospitals, health systems, academic medical centers and large physician groups concerning regulatory and structuring issues related to physician contracting, including practice acquisitions, professional services arrangements and evolving value-based arrangements. Rob regularly assists clients with the design of Stark Law-compliant physician compensation methodologies, including within group practices. Rob has considerable experience troubleshooting existing arrangements, often finding compliant pathways, and has filed a number Stark Law voluntary disclosures with the Centers for Medicare \u0026amp; Medicaid Services when a Stark-compliant pathway could not be identified.\nRob represents health industry clients in transactional matters, including performing healthcare regulatory due diligence in connection with mergers and acquisitions. Rob also advises clinical laboratories regarding CLIA and state law compliance, including in the context of sanction proceedings before the Centers for Medicare \u0026amp; Medicaid Services.\nRob advises clients on federal and state health information privacy issues and has significant experience representing HIPAA covered entities and business associates, as well as medical device and pharmaceutical companies that encounter HIPAA-related issues. He provides advice regarding covered entity and business associate regulated status, proactive compliance, data use and sharing, incident response and breach reporting, de-identification, and clinical research issues.\nRob regularly assists clients with managed care contracting issues, including contract review and negotiation; development of template language; and evaluation of regulated content, including applicability of federal law and state insurance codes. Rob served as the Editor of the American Health Law Association’s Health Plans Contracting Handbook, 7th ed. (2015), and served as Co-Editor of the 5th and 6th editions. Rob also spent time in-house at a national health insurance company advising managed care organization clients on various contracting and regulatory issues before returning to King \u0026amp; Spalding.\nA regular speaker and writer, Rob is ranked as Band 1 for Healthcare in Georgia in Chambers USA Client's Guide to America's Leading Lawyers for Business and also is recognized in recent editions of The Best Lawyers in America and Expert Guides Best of the Best USA. He is a member of the American Health Law Association, the Health Law Section of the American Bar Association, and the State Bar of Georgia, and is a member and past President of the Georgia Academy of Healthcare Attorneys. Rob was named “Lawyer of the Year” for Health Care Law in the 2023 Georgia edition of Best Lawyers. Robert M Keenan Partner \"Rob provides excellent and practical guidance on complex HIPAA topics.\" Chambers USA, 2022 Top Ranked Lawyer, Healthcare Chambers USA, Georgia, 2005-2024 University of Illinois  University of Georgia University of Georgia School of Law Georgia","searchable_name":"Robert M. Keenan III (Rob)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":445387,"version":1,"owner_type":"Person","owner_id":2473,"payload":{"bio":"\u003cp\u003eChris Kenny is a partner in our Healthcare practice and specializes in providing strategic payment and compliance advice to hospitals, health systems, academic medical centers, and other organizations participating in Medicare, Medicaid and commercial insurance plans.\u0026nbsp; For the past nine years, Chris has been recognized by \u003cem\u003eChambers USA\u003c/em\u003e as a leading healthcare lawyer and in 2020 was named a Top Attorney Under 40 by\u0026nbsp;\u003cem\u003eLaw 360\u003c/em\u003e.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith in-depth knowledge of payment systems and regulations, Chris\u0026nbsp;regularly advises in-house lawyers and C-suite executives on the payment implications of major business decisions including facility construction/acquisition,\u0026nbsp;medical staff relations, the operation\u0026nbsp;and expansion of graduate medical education and allied health training programs,\u0026nbsp;organ acquisition program management, participation in the 340B Drug Pricing Program,\u0026nbsp;and telehealth expansion.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eApplying his regulatory and reimbursement experience, Chris represents hospitals in Medicare payment litigation\u0026nbsp;and before Congress and the administrative branch, as well as in\u0026nbsp;False Claims Act investigations by the U.S. Department of Justice.\u003c/p\u003e\n\u003cp\u003eHe strives to provide creative, proactive advice in an ever-changing healthcare regulatory environment, and to vigorously defend his clients\u0026rsquo; positions in payment disputes and government investigations.\u003c/p\u003e\n\u003cp\u003eA member of the Healthcare Financial Management Association and the American Health Lawyers Association, Chris regularly speaks and writes on reimbursement and compliance issues. He is the co-editor of the \u003cem\u003eReimbursement Advisor,\u003c/em\u003e the leading national healthcare reimbursement publication, and serves as co-editor of our firm\u0026rsquo;s award-winning \u003cem\u003eHealth Headlines\u003c/em\u003e, a weekly newsletter summarizing healthcare law and policy developments.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eADMITTED TO PRACTICE IN DISTRICT OF COLUMBIA AND MARYLAND; NOT ADMITTED TO PRACTICE IN FLORIDA\u003c/strong\u003e\u003c/p\u003e","slug":"christopher-kenny","email":"ckenny@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresented the Florida Hospital Association and 12 of its members in a precedent-setting challenge to CMS's exclusion of section 1115 waiver days from the Medicare DSH payment adjustment, resulting in a multi-million dollar victory.\u0026nbsp;\u003cem\u003eSee Bethesda Health v. Azar\u003c/em\u003e, 980 F.3d 121 (D.C. Cir. 2020). Mr. Kenny is currently pursuing the same issue on behalf of dozens more hospitals in Florida, Texas, California, Tennessee and elsewhere, with total amounts in controversy worth hundreds of millions of dollars.\u003c/p\u003e","\u003cp\u003eRepresented 34 hospitals in overturning CMS's unlawful policy understating the so-called \"rural floor,\" generating hundreds of millions of dollars in additional wage-related payments for providers in Arizona, Connecticut, Florida, and elsewhere.\u0026nbsp;\u003cem\u003eCitrus HMA v. Azar\u003c/em\u003e, Case No. 20-00707, 2022 WL 1062990 (D.D.C. 2022).\u003c/p\u003e","\u003cp\u003eSuccessfully represented five major health systems in overturning CMS's disallowance of millions of dollars in financial support for the hospitals' nursing and other training programs. The court noted \"the hosptials are right, and it is not even close.\"\u0026nbsp;\u003cem\u003eMercy Health-St. Vincent Medical Center v. Becerra\u003c/em\u003e, Case No. 22-3578 (D.D.C. 2024).\u003c/p\u003e","\u003cp\u003eRegularly provides day-to-day counseling to more than a dozen major health systems in the establishment and operation of large outpatient provider-based facilities and rural health clinics. Issues involved include the structuring of complex management agreements, joint ventures, 340B considerations, service line collaborations, and hospital-physician relationships.\u003c/p\u003e","\u003cp\u003eSuccessfully represented a Medicaid managed care organization in multiple False Claims Act investigations by local U.S. Attorneys' Offices resulting in declinations.\u003c/p\u003e","\u003cp\u003eRecovered millions of dollars in additional cost reimbursement for an organ procurement organization's clinical laboratory activities.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":116}]},"expertise":[{"id":103,"guid":"103.capabilities","index":0,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":1,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":12,"guid":"12.capabilities","index":4,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":5,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":6,"source":"smartTags"},{"id":114,"guid":"114.capabilities","index":7,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":8,"source":"capabilities"},{"id":1185,"guid":"1185.smart_tags","index":9,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"Kenny","nick_name":"Chris","clerkships":[],"first_name":"Christopher","title_rank":9999,"updated_by":35,"law_schools":[],"middle_name":"P.","name_suffix":"","recognitions":[{"title":"2020 Top Attorneys Under 40 - Healthcare","detail":"Law360"},{"title":"Ranked in Chambers USA for Healthcare 2017-2021","detail":"Chambers USA"},{"title":"Named a Rising Star in Healthcare","detail":"SUPER LAWYERS, 2018"},{"title":"Named a Rising Star in Healthcare","detail":"Super Lawyers, 2017"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eChris Kenny is a partner in our Healthcare practice and specializes in providing strategic payment and compliance advice to hospitals, health systems, academic medical centers, and other organizations participating in Medicare, Medicaid and commercial insurance plans.\u0026nbsp; For the past nine years, Chris has been recognized by \u003cem\u003eChambers USA\u003c/em\u003e as a leading healthcare lawyer and in 2020 was named a Top Attorney Under 40 by\u0026nbsp;\u003cem\u003eLaw 360\u003c/em\u003e.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith in-depth knowledge of payment systems and regulations, Chris\u0026nbsp;regularly advises in-house lawyers and C-suite executives on the payment implications of major business decisions including facility construction/acquisition,\u0026nbsp;medical staff relations, the operation\u0026nbsp;and expansion of graduate medical education and allied health training programs,\u0026nbsp;organ acquisition program management, participation in the 340B Drug Pricing Program,\u0026nbsp;and telehealth expansion.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eApplying his regulatory and reimbursement experience, Chris represents hospitals in Medicare payment litigation\u0026nbsp;and before Congress and the administrative branch, as well as in\u0026nbsp;False Claims Act investigations by the U.S. Department of Justice.\u003c/p\u003e\n\u003cp\u003eHe strives to provide creative, proactive advice in an ever-changing healthcare regulatory environment, and to vigorously defend his clients\u0026rsquo; positions in payment disputes and government investigations.\u003c/p\u003e\n\u003cp\u003eA member of the Healthcare Financial Management Association and the American Health Lawyers Association, Chris regularly speaks and writes on reimbursement and compliance issues. He is the co-editor of the \u003cem\u003eReimbursement Advisor,\u003c/em\u003e the leading national healthcare reimbursement publication, and serves as co-editor of our firm\u0026rsquo;s award-winning \u003cem\u003eHealth Headlines\u003c/em\u003e, a weekly newsletter summarizing healthcare law and policy developments.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eADMITTED TO PRACTICE IN DISTRICT OF COLUMBIA AND MARYLAND; NOT ADMITTED TO PRACTICE IN FLORIDA\u003c/strong\u003e\u003c/p\u003e","matters":["\u003cp\u003eRepresented the Florida Hospital Association and 12 of its members in a precedent-setting challenge to CMS's exclusion of section 1115 waiver days from the Medicare DSH payment adjustment, resulting in a multi-million dollar victory.\u0026nbsp;\u003cem\u003eSee Bethesda Health v. Azar\u003c/em\u003e, 980 F.3d 121 (D.C. Cir. 2020). Mr. Kenny is currently pursuing the same issue on behalf of dozens more hospitals in Florida, Texas, California, Tennessee and elsewhere, with total amounts in controversy worth hundreds of millions of dollars.\u003c/p\u003e","\u003cp\u003eRepresented 34 hospitals in overturning CMS's unlawful policy understating the so-called \"rural floor,\" generating hundreds of millions of dollars in additional wage-related payments for providers in Arizona, Connecticut, Florida, and elsewhere.\u0026nbsp;\u003cem\u003eCitrus HMA v. Azar\u003c/em\u003e, Case No. 20-00707, 2022 WL 1062990 (D.D.C. 2022).\u003c/p\u003e","\u003cp\u003eSuccessfully represented five major health systems in overturning CMS's disallowance of millions of dollars in financial support for the hospitals' nursing and other training programs. The court noted \"the hosptials are right, and it is not even close.\"\u0026nbsp;\u003cem\u003eMercy Health-St. Vincent Medical Center v. Becerra\u003c/em\u003e, Case No. 22-3578 (D.D.C. 2024).\u003c/p\u003e","\u003cp\u003eRegularly provides day-to-day counseling to more than a dozen major health systems in the establishment and operation of large outpatient provider-based facilities and rural health clinics. Issues involved include the structuring of complex management agreements, joint ventures, 340B considerations, service line collaborations, and hospital-physician relationships.\u003c/p\u003e","\u003cp\u003eSuccessfully represented a Medicaid managed care organization in multiple False Claims Act investigations by local U.S. Attorneys' Offices resulting in declinations.\u003c/p\u003e","\u003cp\u003eRecovered millions of dollars in additional cost reimbursement for an organ procurement organization's clinical laboratory activities.\u003c/p\u003e"],"recognitions":[{"title":"2020 Top Attorneys Under 40 - Healthcare","detail":"Law360"},{"title":"Ranked in Chambers USA for Healthcare 2017-2021","detail":"Chambers USA"},{"title":"Named a Rising Star in Healthcare","detail":"SUPER LAWYERS, 2018"},{"title":"Named a Rising Star in Healthcare","detail":"Super Lawyers, 2017"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10000}]},"capability_group_id":2},"created_at":"2026-01-30T19:46:10.000Z","updated_at":"2026-01-30T19:46:10.000Z","searchable_text":"Kenny{{ FIELD }}{:title=\u0026gt;\"2020 Top Attorneys Under 40 - Healthcare\", :detail=\u0026gt;\"Law360\"}{{ FIELD }}{:title=\u0026gt;\"Ranked in Chambers USA for Healthcare 2017-2021\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Named a Rising Star in Healthcare\", :detail=\u0026gt;\"SUPER LAWYERS, 2018\"}{{ FIELD }}{:title=\u0026gt;\"Named a Rising Star in Healthcare\", :detail=\u0026gt;\"Super Lawyers, 2017\"}{{ FIELD }}Represented the Florida Hospital Association and 12 of its members in a precedent-setting challenge to CMS's exclusion of section 1115 waiver days from the Medicare DSH payment adjustment, resulting in a multi-million dollar victory. See Bethesda Health v. Azar, 980 F.3d 121 (D.C. Cir. 2020). Mr. Kenny is currently pursuing the same issue on behalf of dozens more hospitals in Florida, Texas, California, Tennessee and elsewhere, with total amounts in controversy worth hundreds of millions of dollars.{{ FIELD }}Represented 34 hospitals in overturning CMS's unlawful policy understating the so-called \"rural floor,\" generating hundreds of millions of dollars in additional wage-related payments for providers in Arizona, Connecticut, Florida, and elsewhere. Citrus HMA v. Azar, Case No. 20-00707, 2022 WL 1062990 (D.D.C. 2022).{{ FIELD }}Successfully represented five major health systems in overturning CMS's disallowance of millions of dollars in financial support for the hospitals' nursing and other training programs. The court noted \"the hosptials are right, and it is not even close.\" Mercy Health-St. Vincent Medical Center v. Becerra, Case No. 22-3578 (D.D.C. 2024).{{ FIELD }}Regularly provides day-to-day counseling to more than a dozen major health systems in the establishment and operation of large outpatient provider-based facilities and rural health clinics. Issues involved include the structuring of complex management agreements, joint ventures, 340B considerations, service line collaborations, and hospital-physician relationships.{{ FIELD }}Successfully represented a Medicaid managed care organization in multiple False Claims Act investigations by local U.S. Attorneys' Offices resulting in declinations.{{ FIELD }}Recovered millions of dollars in additional cost reimbursement for an organ procurement organization's clinical laboratory activities.{{ FIELD }}Chris Kenny is a partner in our Healthcare practice and specializes in providing strategic payment and compliance advice to hospitals, health systems, academic medical centers, and other organizations participating in Medicare, Medicaid and commercial insurance plans.  For the past nine years, Chris has been recognized by Chambers USA as a leading healthcare lawyer and in 2020 was named a Top Attorney Under 40 by Law 360.\nWith in-depth knowledge of payment systems and regulations, Chris regularly advises in-house lawyers and C-suite executives on the payment implications of major business decisions including facility construction/acquisition, medical staff relations, the operation and expansion of graduate medical education and allied health training programs, organ acquisition program management, participation in the 340B Drug Pricing Program, and telehealth expansion.  \nApplying his regulatory and reimbursement experience, Chris represents hospitals in Medicare payment litigation and before Congress and the administrative branch, as well as in False Claims Act investigations by the U.S. Department of Justice.\nHe strives to provide creative, proactive advice in an ever-changing healthcare regulatory environment, and to vigorously defend his clients’ positions in payment disputes and government investigations.\nA member of the Healthcare Financial Management Association and the American Health Lawyers Association, Chris regularly speaks and writes on reimbursement and compliance issues. He is the co-editor of the Reimbursement Advisor, the leading national healthcare reimbursement publication, and serves as co-editor of our firm’s award-winning Health Headlines, a weekly newsletter summarizing healthcare law and policy developments.\nADMITTED TO PRACTICE IN DISTRICT OF COLUMBIA AND MARYLAND; NOT ADMITTED TO PRACTICE IN FLORIDA Christopher P Kenny Partner 2020 Top Attorneys Under 40 - Healthcare Law360 Ranked in Chambers USA for Healthcare 2017-2021 Chambers USA Named a Rising Star in Healthcare SUPER LAWYERS, 2018 Named a Rising Star in Healthcare Super Lawyers, 2017 Northwestern University Northwestern Pritzker School of Law George Washington University George Washington University Law School U.S. Court of Appeals for the D.C. Circuit U.S. District Court for the District of Columbia District of Columbia Maryland American Health Lawyers Association Healthcare Financial Management Association Represented the Florida Hospital Association and 12 of its members in a precedent-setting challenge to CMS's exclusion of section 1115 waiver days from the Medicare DSH payment adjustment, resulting in a multi-million dollar victory. See Bethesda Health v. Azar, 980 F.3d 121 (D.C. Cir. 2020). Mr. Kenny is currently pursuing the same issue on behalf of dozens more hospitals in Florida, Texas, California, Tennessee and elsewhere, with total amounts in controversy worth hundreds of millions of dollars. Represented 34 hospitals in overturning CMS's unlawful policy understating the so-called \"rural floor,\" generating hundreds of millions of dollars in additional wage-related payments for providers in Arizona, Connecticut, Florida, and elsewhere. Citrus HMA v. Azar, Case No. 20-00707, 2022 WL 1062990 (D.D.C. 2022). Successfully represented five major health systems in overturning CMS's disallowance of millions of dollars in financial support for the hospitals' nursing and other training programs. The court noted \"the hosptials are right, and it is not even close.\" Mercy Health-St. Vincent Medical Center v. Becerra, Case No. 22-3578 (D.D.C. 2024). Regularly provides day-to-day counseling to more than a dozen major health systems in the establishment and operation of large outpatient provider-based facilities and rural health clinics. Issues involved include the structuring of complex management agreements, joint ventures, 340B considerations, service line collaborations, and hospital-physician relationships. Successfully represented a Medicaid managed care organization in multiple False Claims Act investigations by local U.S. Attorneys' Offices resulting in declinations. Recovered millions of dollars in additional cost reimbursement for an organ procurement organization's clinical laboratory activities.","searchable_name":"Christopher P. Kenny (Chris)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":445251,"version":1,"owner_type":"Person","owner_id":7300,"payload":{"bio":"\u003cp\u003eCat Kirkland is based in Washington, D.C. and is a partner in the firm\u0026rsquo;s Healthcare practice. Cat works closely with hospitals, providers and related stakeholders on reimbursement issues, policy development, financial modeling and business operations. Known for her collaborative, solution-oriented approach, Cat thrives on becoming a trusted partner for each client and takes pride in helping providers navigate challenging and complex legal and reimbursement environments.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eCat\u0026rsquo;s reimbursement experience includes advising clients on state-directed payment initiatives, Medicaid rate modeling, program financing, disproportionate share hospital (DSH) programs, upper payment limit (UPL) arrangements and value-based or incentive-driven payment models. She also regularly counsels providers in reimbursement disputes with commercial and Medicare Advantage payors, including those involving the 340B Drug Pricing Program.\u003c/p\u003e\n\u003cp\u003eOutside the office, Cat enjoys spending time with her husband and three children, traveling and volunteering in her community.\u003c/p\u003e","slug":"catherine-kirkland","email":"ckirkland@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresented a children\u0026rsquo;s hospital in Medicaid reimbursement strategy, leading advocacy and financial modeling efforts that secured inclusion of the hospital in a supplemental Medicaid program through a regulatory exception, resulting in substantial new funding for the hospital.\u003c/p\u003e","\u003cp\u003eRepresented group of hospitals in the development of complex Medicaid financial models and strategic advocacy to support expansion of a directed payment program to a new beneficiary population, resulting in significant new funding for participating providers throughout the state.\u003c/p\u003e","\u003cp\u003eConducted comprehensive Medicaid market analyses for psychiatric hospitals entering new state footprints, assessing potential financial impact and reimbursement opportunities. Provided private equity clients with data-driven insights and modeling to inform investment decisions and strategy for expansion.\u003c/p\u003e","\u003cp\u003eRepresented a large healthcare system in arbitration against a national Medicare Advantage plan resulting in a decisive win and significant financial recovery for the system.\u003c/p\u003e","\u003cp\u003eRegularly analyze and prepare Medicaid DSH applications and audits, identifying new funding opportunities for clients and assisting in averting potential recoupments.\u003c/p\u003e","\u003cp\u003eAssisted clients in modeling the Medicaid financial impact of the One Big Beautiful Bill, developing a variety of scenarios to consider financing, projected payments, and potential operational changes. Provided actionable insights to help clients plan strategically and adapt to evolving policy and market conditions.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":3,"source":"smartTags"},{"id":740,"guid":"740.smart_tags","index":4,"source":"smartTags"}],"is_active":true,"last_name":"Kirkland","nick_name":"Cat","clerkships":[],"first_name":"Catherine","title_rank":9999,"updated_by":34,"law_schools":[{"id":2055,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2011-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/catherine-stanford-kirkland-a074b055/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eCat Kirkland is based in Washington, D.C. and is a partner in the firm\u0026rsquo;s Healthcare practice. Cat works closely with hospitals, providers and related stakeholders on reimbursement issues, policy development, financial modeling and business operations. Known for her collaborative, solution-oriented approach, Cat thrives on becoming a trusted partner for each client and takes pride in helping providers navigate challenging and complex legal and reimbursement environments.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eCat\u0026rsquo;s reimbursement experience includes advising clients on state-directed payment initiatives, Medicaid rate modeling, program financing, disproportionate share hospital (DSH) programs, upper payment limit (UPL) arrangements and value-based or incentive-driven payment models. She also regularly counsels providers in reimbursement disputes with commercial and Medicare Advantage payors, including those involving the 340B Drug Pricing Program.\u003c/p\u003e\n\u003cp\u003eOutside the office, Cat enjoys spending time with her husband and three children, traveling and volunteering in her community.\u003c/p\u003e","matters":["\u003cp\u003eRepresented a children\u0026rsquo;s hospital in Medicaid reimbursement strategy, leading advocacy and financial modeling efforts that secured inclusion of the hospital in a supplemental Medicaid program through a regulatory exception, resulting in substantial new funding for the hospital.\u003c/p\u003e","\u003cp\u003eRepresented group of hospitals in the development of complex Medicaid financial models and strategic advocacy to support expansion of a directed payment program to a new beneficiary population, resulting in significant new funding for participating providers throughout the state.\u003c/p\u003e","\u003cp\u003eConducted comprehensive Medicaid market analyses for psychiatric hospitals entering new state footprints, assessing potential financial impact and reimbursement opportunities. Provided private equity clients with data-driven insights and modeling to inform investment decisions and strategy for expansion.\u003c/p\u003e","\u003cp\u003eRepresented a large healthcare system in arbitration against a national Medicare Advantage plan resulting in a decisive win and significant financial recovery for the system.\u003c/p\u003e","\u003cp\u003eRegularly analyze and prepare Medicaid DSH applications and audits, identifying new funding opportunities for clients and assisting in averting potential recoupments.\u003c/p\u003e","\u003cp\u003eAssisted clients in modeling the Medicaid financial impact of the One Big Beautiful Bill, developing a variety of scenarios to consider financing, projected payments, and potential operational changes. Provided actionable insights to help clients plan strategically and adapt to evolving policy and market conditions.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":13319}]},"capability_group_id":2},"created_at":"2026-01-26T14:43:19.000Z","updated_at":"2026-01-26T14:43:19.000Z","searchable_text":"Kirkland{{ FIELD }}Represented a children’s hospital in Medicaid reimbursement strategy, leading advocacy and financial modeling efforts that secured inclusion of the hospital in a supplemental Medicaid program through a regulatory exception, resulting in substantial new funding for the hospital.{{ FIELD }}Represented group of hospitals in the development of complex Medicaid financial models and strategic advocacy to support expansion of a directed payment program to a new beneficiary population, resulting in significant new funding for participating providers throughout the state.{{ FIELD }}Conducted comprehensive Medicaid market analyses for psychiatric hospitals entering new state footprints, assessing potential financial impact and reimbursement opportunities. Provided private equity clients with data-driven insights and modeling to inform investment decisions and strategy for expansion.{{ FIELD }}Represented a large healthcare system in arbitration against a national Medicare Advantage plan resulting in a decisive win and significant financial recovery for the system.{{ FIELD }}Regularly analyze and prepare Medicaid DSH applications and audits, identifying new funding opportunities for clients and assisting in averting potential recoupments.{{ FIELD }}Assisted clients in modeling the Medicaid financial impact of the One Big Beautiful Bill, developing a variety of scenarios to consider financing, projected payments, and potential operational changes. Provided actionable insights to help clients plan strategically and adapt to evolving policy and market conditions.{{ FIELD }}Cat Kirkland is based in Washington, D.C. and is a partner in the firm’s Healthcare practice. Cat works closely with hospitals, providers and related stakeholders on reimbursement issues, policy development, financial modeling and business operations. Known for her collaborative, solution-oriented approach, Cat thrives on becoming a trusted partner for each client and takes pride in helping providers navigate challenging and complex legal and reimbursement environments.\nCat’s reimbursement experience includes advising clients on state-directed payment initiatives, Medicaid rate modeling, program financing, disproportionate share hospital (DSH) programs, upper payment limit (UPL) arrangements and value-based or incentive-driven payment models. She also regularly counsels providers in reimbursement disputes with commercial and Medicare Advantage payors, including those involving the 340B Drug Pricing Program.\nOutside the office, Cat enjoys spending time with her husband and three children, traveling and volunteering in her community. Partner The University of Texas at Austin The University of Texas School of Law The University of Texas at Austin The University of Texas School of Law Alabama Texas Texas Bar Association The American Health Lawyers Association Mobile Bar Association Represented a children’s hospital in Medicaid reimbursement strategy, leading advocacy and financial modeling efforts that secured inclusion of the hospital in a supplemental Medicaid program through a regulatory exception, resulting in substantial new funding for the hospital. Represented group of hospitals in the development of complex Medicaid financial models and strategic advocacy to support expansion of a directed payment program to a new beneficiary population, resulting in significant new funding for participating providers throughout the state. Conducted comprehensive Medicaid market analyses for psychiatric hospitals entering new state footprints, assessing potential financial impact and reimbursement opportunities. Provided private equity clients with data-driven insights and modeling to inform investment decisions and strategy for expansion. Represented a large healthcare system in arbitration against a national Medicare Advantage plan resulting in a decisive win and significant financial recovery for the system. Regularly analyze and prepare Medicaid DSH applications and audits, identifying new funding opportunities for clients and assisting in averting potential recoupments. Assisted clients in modeling the Medicaid financial impact of the One Big Beautiful Bill, developing a variety of scenarios to consider financing, projected payments, and potential operational changes. Provided actionable insights to help clients plan strategically and adapt to evolving policy and market conditions.","searchable_name":"Catherine Kirkland (Cat)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null},{"id":440298,"version":1,"owner_type":"Person","owner_id":2100,"payload":{"bio":"\u003cp\u003eAmanda Klingler is a partner in the firm\u0026rsquo;s Washington, D.C. and Chicago offices with extensive experience advising life science clients.\u0026nbsp; As a partner in the firm's FDA and Life Sciences practice, Amanda advises pharmaceutical, medical device and biotech companies and pharmacies, on a wide range of regulatory matters, enforcement actions, civil litigation, investigations, product liability litigation, and compliance counseling.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAmanda counsels clients on pre- and post-marketing regulatory activities and strategies, including obtaining FDA approval and clearance for medical products.\u0026nbsp; Amanda also regularly advises clients on product labeling, adverse event reporting, product safety issues, recalls/field corrections, import detention, and advertising and promotion issues.\u0026nbsp; She counsels clients on quality system and manufacturing practices for drugs and medical devices and factory inspections, including conducting mock inspections and working closely with and providing advice to clients during the inspection, and provide guidance in responding to FDA investigational observations (FDA-483 forms), and warning letters.\u0026nbsp;\u0026nbsp;Amanda, as a co-leader of the firm\u0026rsquo;s AI/ML Tactical Operations team, also frequently advises clients on the use of AI/ML during the life cycle of drugs and medical devices, including digital health products.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmanda advises clients during internal and government investigations.\u0026nbsp; She also assists in the negotiation and management of several consent decrees of injunction for pharmaceutical, medical device, food companies and compounding pharmacies.\u003c/p\u003e\n\u003cp\u003eAmanda works closely with the firm's product liability team and is experienced in handling FDA issues in product liability litigation, including the development of supporting evidence, writing briefs, and preparing expert witnesses to testify.\u003c/p\u003e\n\u003cp\u003eAmanda also has significant experience and expertise in FDA's regulation of tobacco products.\u003c/p\u003e","slug":"amanda-klingler","email":"aklingler@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cem\u003ePhillips Morris USA v. FDA,\u0026nbsp;\u003c/em\u003e202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products.\u003c/p\u003e","\u003cp\u003eMember of a King \u0026amp; Spalding team serving as national coordinating counsel and trial counsel in\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eproduct liability litigation\u003c/strong\u003einvolving GlaxoSmithKline\u0026rsquo;s antidepressant Paxil\u0026reg;, including in the Philadelphia Court of Common Pleas Mass Tort Program. Experience includes preparing fact and expert witnesses on FDA issues and briefing motions\u0026nbsp;\u003cem data-redactor-tag=\"em\"\u003ein limine\u003c/em\u003e\u0026nbsp;and\u0026nbsp;\u003cem data-redactor-tag=\"em\"\u003eDaubert\u003c/em\u003echallenges.\u003c/p\u003e","\u003cp\u003eMember of a King \u0026amp; Spalding team representing the\u0026nbsp;\u003cstrong\u003emanufacturer of FDA-cleared surgical gowns\u0026nbsp;\u003c/strong\u003ein nationwide litigation concerning the design, labeling, advertising and manufacture of the devices, including: a federal class action trial, the verdict from which is on appeal to the Ninth Circuit; a\u0026nbsp;\u003cem\u003equi tam\u0026nbsp;\u003c/em\u003esuit brought under the Federal False Claims Act in which the court granted defendants' motion to dismiss; and a federal Lanham Act lawsuit concerning allegations of false marketing. Experience includes working extensively with the Company's regulatory expert witness on the FDA-related issues in the litigation, leading the development of the Company's expert report and preparing the witness for his trial testimony.\u003c/p\u003e","\u003cp\u003eAssisted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ecompanies in preparing for FDA inspections,\u003c/strong\u003e\u0026nbsp;developing responses to FDA investigational observations (FDA-483 forms), and warning letters.\u003c/p\u003e","\u003cp\u003eAssisted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device companies\u003c/strong\u003e\u0026nbsp;under investigation by FDA and the U.S. Department of Justice Office for alleged violations of the FDCA.\u003c/p\u003e","\u003cp\u003eConducted\u0026nbsp;\u003cstrong\u003einternal investigations of pharmaceutical medical device manufacturers\u003c/strong\u003e\u0026nbsp;into potential quality systems and advertising and promotion violations to develop a risk profile and recommendation for reducing potential liability and risk exposure.\u003c/p\u003e","\u003cp\u003eConducted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eFDA regulatory due diligence reviews\u003c/strong\u003e\u0026nbsp;of target medical device, pharmaceutical manufacturers, and compounding pharmacies.\u003c/p\u003e","\u003cp\u003eCounseled companies on\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eradiation-emitting product requirements\u003c/strong\u003e\u0026nbsp;under the FDCA.\u003c/p\u003e","\u003cp\u003eCounseled companies on\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003elabeling and promotion requirements\u003c/strong\u003e\u0026nbsp;for FDA-regulated products.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eUnited States v. Franck\u0026rsquo;s Lab\u003c/em\u003e, 2011 WL 4031102 (M.D. Fla. Sept. 12, 2011). Lead associate for\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eFranck\u0026rsquo;s Lab\u003c/strong\u003e\u0026nbsp;in successful defense of FDA enforcement action contending that traditional, state-licensed pharmacy compounding of veterinary medications violates FDA\u0026rsquo;s statute. Also served as the lead associate for Franck\u0026rsquo;s Lab in other FDA regulatory and state board of pharmacy matters.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eHill Dermaceuticals, Inc. v.\u003c/em\u003e\u0026nbsp;FDA, No. 1:11-cv-01950 (D.D.C.). Lead associate representing\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003einnovator drug manufacturer\u003c/strong\u003e\u0026nbsp;in litigation seeking to require FDA to withdraw its approval of purported generic formulations of manufacturer\u0026rsquo;s brand name products.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":174}]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":3,"source":"capabilities"},{"id":114,"guid":"114.capabilities","index":4,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":5,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":6,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":7,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":8,"source":"smartTags"},{"id":128,"guid":"128.capabilities","index":9,"source":"capabilities"},{"id":133,"guid":"133.capabilities","index":10,"source":"capabilities"},{"id":1206,"guid":"1206.smart_tags","index":11,"source":"smartTags"}],"is_active":true,"last_name":"Klingler","nick_name":"Amanda","clerkships":[],"first_name":"Amanda","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"J.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAmanda Klingler is a partner in the firm\u0026rsquo;s Washington, D.C. and Chicago offices with extensive experience advising life science clients.\u0026nbsp; As a partner in the firm's FDA and Life Sciences practice, Amanda advises pharmaceutical, medical device and biotech companies and pharmacies, on a wide range of regulatory matters, enforcement actions, civil litigation, investigations, product liability litigation, and compliance counseling.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAmanda counsels clients on pre- and post-marketing regulatory activities and strategies, including obtaining FDA approval and clearance for medical products.\u0026nbsp; Amanda also regularly advises clients on product labeling, adverse event reporting, product safety issues, recalls/field corrections, import detention, and advertising and promotion issues.\u0026nbsp; She counsels clients on quality system and manufacturing practices for drugs and medical devices and factory inspections, including conducting mock inspections and working closely with and providing advice to clients during the inspection, and provide guidance in responding to FDA investigational observations (FDA-483 forms), and warning letters.\u0026nbsp;\u0026nbsp;Amanda, as a co-leader of the firm\u0026rsquo;s AI/ML Tactical Operations team, also frequently advises clients on the use of AI/ML during the life cycle of drugs and medical devices, including digital health products.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmanda advises clients during internal and government investigations.\u0026nbsp; She also assists in the negotiation and management of several consent decrees of injunction for pharmaceutical, medical device, food companies and compounding pharmacies.\u003c/p\u003e\n\u003cp\u003eAmanda works closely with the firm's product liability team and is experienced in handling FDA issues in product liability litigation, including the development of supporting evidence, writing briefs, and preparing expert witnesses to testify.\u003c/p\u003e\n\u003cp\u003eAmanda also has significant experience and expertise in FDA's regulation of tobacco products.\u003c/p\u003e","matters":["\u003cp\u003e\u003cem\u003ePhillips Morris USA v. FDA,\u0026nbsp;\u003c/em\u003e202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products.\u003c/p\u003e","\u003cp\u003eMember of a King \u0026amp; Spalding team serving as national coordinating counsel and trial counsel in\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eproduct liability litigation\u003c/strong\u003einvolving GlaxoSmithKline\u0026rsquo;s antidepressant Paxil\u0026reg;, including in the Philadelphia Court of Common Pleas Mass Tort Program. Experience includes preparing fact and expert witnesses on FDA issues and briefing motions\u0026nbsp;\u003cem data-redactor-tag=\"em\"\u003ein limine\u003c/em\u003e\u0026nbsp;and\u0026nbsp;\u003cem data-redactor-tag=\"em\"\u003eDaubert\u003c/em\u003echallenges.\u003c/p\u003e","\u003cp\u003eMember of a King \u0026amp; Spalding team representing the\u0026nbsp;\u003cstrong\u003emanufacturer of FDA-cleared surgical gowns\u0026nbsp;\u003c/strong\u003ein nationwide litigation concerning the design, labeling, advertising and manufacture of the devices, including: a federal class action trial, the verdict from which is on appeal to the Ninth Circuit; a\u0026nbsp;\u003cem\u003equi tam\u0026nbsp;\u003c/em\u003esuit brought under the Federal False Claims Act in which the court granted defendants' motion to dismiss; and a federal Lanham Act lawsuit concerning allegations of false marketing. Experience includes working extensively with the Company's regulatory expert witness on the FDA-related issues in the litigation, leading the development of the Company's expert report and preparing the witness for his trial testimony.\u003c/p\u003e","\u003cp\u003eAssisted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ecompanies in preparing for FDA inspections,\u003c/strong\u003e\u0026nbsp;developing responses to FDA investigational observations (FDA-483 forms), and warning letters.\u003c/p\u003e","\u003cp\u003eAssisted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical and medical device companies\u003c/strong\u003e\u0026nbsp;under investigation by FDA and the U.S. Department of Justice Office for alleged violations of the FDCA.\u003c/p\u003e","\u003cp\u003eConducted\u0026nbsp;\u003cstrong\u003einternal investigations of pharmaceutical medical device manufacturers\u003c/strong\u003e\u0026nbsp;into potential quality systems and advertising and promotion violations to develop a risk profile and recommendation for reducing potential liability and risk exposure.\u003c/p\u003e","\u003cp\u003eConducted\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eFDA regulatory due diligence reviews\u003c/strong\u003e\u0026nbsp;of target medical device, pharmaceutical manufacturers, and compounding pharmacies.\u003c/p\u003e","\u003cp\u003eCounseled companies on\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eradiation-emitting product requirements\u003c/strong\u003e\u0026nbsp;under the FDCA.\u003c/p\u003e","\u003cp\u003eCounseled companies on\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003elabeling and promotion requirements\u003c/strong\u003e\u0026nbsp;for FDA-regulated products.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eUnited States v. Franck\u0026rsquo;s Lab\u003c/em\u003e, 2011 WL 4031102 (M.D. Fla. Sept. 12, 2011). Lead associate for\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eFranck\u0026rsquo;s Lab\u003c/strong\u003e\u0026nbsp;in successful defense of FDA enforcement action contending that traditional, state-licensed pharmacy compounding of veterinary medications violates FDA\u0026rsquo;s statute. Also served as the lead associate for Franck\u0026rsquo;s Lab in other FDA regulatory and state board of pharmacy matters.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eHill Dermaceuticals, Inc. v.\u003c/em\u003e\u0026nbsp;FDA, No. 1:11-cv-01950 (D.D.C.). Lead associate representing\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003einnovator drug manufacturer\u003c/strong\u003e\u0026nbsp;in litigation seeking to require FDA to withdraw its approval of purported generic formulations of manufacturer\u0026rsquo;s brand name products.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4350}]},"capability_group_id":2},"created_at":"2025-10-08T19:11:18.000Z","updated_at":"2025-10-08T19:11:18.000Z","searchable_text":"Klingler{{ FIELD }}Phillips Morris USA v. FDA, 202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products.{{ FIELD }}Member of a King \u0026amp; Spalding team serving as national coordinating counsel and trial counsel in product liability litigationinvolving GlaxoSmithKline’s antidepressant Paxil®, including in the Philadelphia Court of Common Pleas Mass Tort Program. Experience includes preparing fact and expert witnesses on FDA issues and briefing motions in limine and Daubertchallenges.{{ FIELD }}Member of a King \u0026amp; Spalding team representing the manufacturer of FDA-cleared surgical gowns in nationwide litigation concerning the design, labeling, advertising and manufacture of the devices, including: a federal class action trial, the verdict from which is on appeal to the Ninth Circuit; a qui tam suit brought under the Federal False Claims Act in which the court granted defendants' motion to dismiss; and a federal Lanham Act lawsuit concerning allegations of false marketing. Experience includes working extensively with the Company's regulatory expert witness on the FDA-related issues in the litigation, leading the development of the Company's expert report and preparing the witness for his trial testimony.{{ FIELD }}Assisted companies in preparing for FDA inspections, developing responses to FDA investigational observations (FDA-483 forms), and warning letters.{{ FIELD }}Assisted pharmaceutical and medical device companies under investigation by FDA and the U.S. Department of Justice Office for alleged violations of the FDCA.{{ FIELD }}Conducted internal investigations of pharmaceutical medical device manufacturers into potential quality systems and advertising and promotion violations to develop a risk profile and recommendation for reducing potential liability and risk exposure.{{ FIELD }}Conducted FDA regulatory due diligence reviews of target medical device, pharmaceutical manufacturers, and compounding pharmacies.{{ FIELD }}Counseled companies on radiation-emitting product requirements under the FDCA.{{ FIELD }}Counseled companies on labeling and promotion requirements for FDA-regulated products.{{ FIELD }}United States v. Franck’s Lab, 2011 WL 4031102 (M.D. Fla. Sept. 12, 2011). Lead associate for Franck’s Lab in successful defense of FDA enforcement action contending that traditional, state-licensed pharmacy compounding of veterinary medications violates FDA’s statute. Also served as the lead associate for Franck’s Lab in other FDA regulatory and state board of pharmacy matters.{{ FIELD }}Hill Dermaceuticals, Inc. v. FDA, No. 1:11-cv-01950 (D.D.C.). Lead associate representing innovator drug manufacturer in litigation seeking to require FDA to withdraw its approval of purported generic formulations of manufacturer’s brand name products.{{ FIELD }}Amanda Klingler is a partner in the firm’s Washington, D.C. and Chicago offices with extensive experience advising life science clients.  As a partner in the firm's FDA and Life Sciences practice, Amanda advises pharmaceutical, medical device and biotech companies and pharmacies, on a wide range of regulatory matters, enforcement actions, civil litigation, investigations, product liability litigation, and compliance counseling. \nAmanda counsels clients on pre- and post-marketing regulatory activities and strategies, including obtaining FDA approval and clearance for medical products.  Amanda also regularly advises clients on product labeling, adverse event reporting, product safety issues, recalls/field corrections, import detention, and advertising and promotion issues.  She counsels clients on quality system and manufacturing practices for drugs and medical devices and factory inspections, including conducting mock inspections and working closely with and providing advice to clients during the inspection, and provide guidance in responding to FDA investigational observations (FDA-483 forms), and warning letters.  Amanda, as a co-leader of the firm’s AI/ML Tactical Operations team, also frequently advises clients on the use of AI/ML during the life cycle of drugs and medical devices, including digital health products. \nAmanda advises clients during internal and government investigations.  She also assists in the negotiation and management of several consent decrees of injunction for pharmaceutical, medical device, food companies and compounding pharmacies.\nAmanda works closely with the firm's product liability team and is experienced in handling FDA issues in product liability litigation, including the development of supporting evidence, writing briefs, and preparing expert witnesses to testify.\nAmanda also has significant experience and expertise in FDA's regulation of tobacco products. Amanda J Klingler Partner University of Richmond University of Richmond School of Law Saint Louis University Saint Louis University School of Law Loyola University Chicago Loyola University Chicago School of Law District of Columbia Illinois Phillips Morris USA v. FDA, 202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products. Member of a King \u0026amp; Spalding team serving as national coordinating counsel and trial counsel in product liability litigationinvolving GlaxoSmithKline’s antidepressant Paxil®, including in the Philadelphia Court of Common Pleas Mass Tort Program. Experience includes preparing fact and expert witnesses on FDA issues and briefing motions in limine and Daubertchallenges. Member of a King \u0026amp; Spalding team representing the manufacturer of FDA-cleared surgical gowns in nationwide litigation concerning the design, labeling, advertising and manufacture of the devices, including: a federal class action trial, the verdict from which is on appeal to the Ninth Circuit; a qui tam suit brought under the Federal False Claims Act in which the court granted defendants' motion to dismiss; and a federal Lanham Act lawsuit concerning allegations of false marketing. Experience includes working extensively with the Company's regulatory expert witness on the FDA-related issues in the litigation, leading the development of the Company's expert report and preparing the witness for his trial testimony. Assisted companies in preparing for FDA inspections, developing responses to FDA investigational observations (FDA-483 forms), and warning letters. Assisted pharmaceutical and medical device companies under investigation by FDA and the U.S. Department of Justice Office for alleged violations of the FDCA. Conducted internal investigations of pharmaceutical medical device manufacturers into potential quality systems and advertising and promotion violations to develop a risk profile and recommendation for reducing potential liability and risk exposure. Conducted FDA regulatory due diligence reviews of target medical device, pharmaceutical manufacturers, and compounding pharmacies. Counseled companies on radiation-emitting product requirements under the FDCA. Counseled companies on labeling and promotion requirements for FDA-regulated products. United States v. Franck’s Lab, 2011 WL 4031102 (M.D. Fla. Sept. 12, 2011). Lead associate for Franck’s Lab in successful defense of FDA enforcement action contending that traditional, state-licensed pharmacy compounding of veterinary medications violates FDA’s statute. Also served as the lead associate for Franck’s Lab in other FDA regulatory and state board of pharmacy matters. Hill Dermaceuticals, Inc. v. FDA, No. 1:11-cv-01950 (D.D.C.). Lead associate representing innovator drug manufacturer in litigation seeking to require FDA to withdraw its approval of purported generic formulations of manufacturer’s brand name products.","searchable_name":"Amanda J. Klingler","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":441625,"version":1,"owner_type":"Person","owner_id":673,"payload":{"bio":"\u003cp\u003eAlec Koch is a co-leader of our Securities Enforcement and Regulation practice and a former Assistant Director with the Securities and Exchange Commission's Division of Enforcement.\u0026nbsp; He represents public companies, financial institutions, boards of directors, and individuals in securities enforcement and anti-corruption investigations before the SEC, DOJ, PCAOB, and other regulatory authorities.\u0026nbsp; Nationally ranked by \u003cem\u003eChambers USA\u003c/em\u003e, Alec is described as having \"broad market approval for his enforcement-side practice.\"\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;Alec also regularly conducts internal investigations on behalf of companies and board committees, often involving multiple jurisdictions,\u0026nbsp;and advises clients on regulatory compliance and corporate governance issues.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAt the SEC, Alec supervised investigations of all types, including matters involving public company accounting and disclosure; The Foreign Corrupt Practices Act; insider trading; regulated entities such as broker-dealers,\u0026nbsp;investment advisers,\u0026nbsp;and credit rating agencies; market manipulation; and securities offerings.\u0026nbsp; He served in multiple leadership roles, including as a member of the Division of Enforcement\u0026rsquo;s Broker-Dealer Task Force, as the co-chair of the Division's\u0026nbsp;Priorities and Resources Subcommittee, and as a liaison\u0026nbsp;between the Division of Enforcement and the SEC\u0026rsquo;s Office of Credit Ratings.\u003c/p\u003e\n\u003cp\u003eAlec\u0026nbsp;serves\u0026nbsp;on the board of directors of Legal Aid D.C.\u0026nbsp;and the Ethics Research Center, a\u0026nbsp;non-profit organization that works to assist public companies and other institutions with building strong ethics and compliance\u0026nbsp;programs.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to working at the\u0026nbsp;SEC, Alec was an associate at King \u0026amp; Spalding from 1997-2002. He rejoined the firm in 2016.\u003c/p\u003e","slug":"alec-koch","email":"akoch@kslaw.com","phone":"+1 202 740 4863","matters":["\u003cp\u003eRepresenting a\u0026nbsp;\u003cstrong\u003eprovider and operator of compression infrastructure used in the production and transfer of oil and natural gas\u003c/strong\u003e\u0026nbsp;in an investigation related to payments potentially made to Mexican cartels designated as foreign terrorist organizations (FTOs).\u003c/p\u003e","\u003cp\u003eRepresenting the\u0026nbsp;\u003cstrong\u003eaudit committee of a global non-clinical global drug development company\u003c/strong\u003e\u0026nbsp;in an internal investigation related to potential FCPA and disclosure violations.\u003c/p\u003e","\u003cp\u003eRepresenting a\u0026nbsp;\u003cstrong\u003eBig Four accounting firm\u003c/strong\u003e\u0026nbsp;in investigations and securities litigation resulting from the sudden closure of several banks for which the firm acted as external auditor.\u003c/p\u003e","\u003cp\u003eRepresenting the\u0026nbsp;\u003cstrong\u003eCISO of a software development company\u003c/strong\u003e\u0026nbsp;in a first-of-its-kind SEC enforcement action relating to the company's disclosures concerning cybersecurity.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003eprovider of life and health insurance\u003c/strong\u003e\u0026nbsp;in SEC and DOJ investigations related to allegations made by short sellers regarding the company's financial performance and independent agents. The investigations were closed without enforcement action.\u003c/p\u003e","\u003cp\u003eServed as the Independent Compliance Consultant for a\u0026nbsp;\u003cstrong\u003eregistered clearing agency\u003c/strong\u003e\u0026nbsp;in connection with its SEC settlement relating to liquidity arrangements.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003emultinational healthcare company\u003c/strong\u003e\u0026nbsp;in connection with its continuing self-reporting obligations under an FCPA settlement with the DOJ and SEC.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003eglobal manufacturing company\u003c/strong\u003e\u0026nbsp;in an SEC investigation of potential FCPA violations in South America that was closed without enforcement action.\u003c/p\u003e","\u003cp\u003eRepresenting the Audit Committee of\u0026nbsp;\u003cstrong\u003ea space infrastructure development company\u003c/strong\u003e\u0026nbsp;in an independent investigation of accounting and employment allegations raised by a former employee.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003eglobal manufacturing company\u003c/strong\u003e\u0026nbsp;in an SEC investigation concerning air emissions-related issues that was closed without enforcement action.\u003c/p\u003e","\u003cp\u003eRepresented an\u0026nbsp;\u003cstrong\u003einternational chemical company\u0026nbsp;\u003c/strong\u003ein a negotiated resolution of anti-corruption investigations conducted by U.S. and Dutch authorities.\u003c/p\u003e","\u003cp\u003eRepresented the\u0026nbsp;\u003cstrong\u003eaudit committee of a public biopharmaceutical company\u003c/strong\u003e\u0026nbsp;in an internal investigation and related government investigations into allegations of accounting fraud and whistleblower retaliation.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003epublic company provider of services to the healthcare industry\u003c/strong\u003e\u0026nbsp;in an SEC investigation of earnings-related disclosures that was resolved on favorable terms.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003epublic pharmaceutical company\u003c/strong\u003e\u0026nbsp;in an SEC investigation of potential selective disclosures and Reg FD violations that was resolved on favorable terms.\u003c/p\u003e","\u003cp\u003eRepresented the\u003cstrong\u003e\u0026nbsp;independent directors of a commercial flooring company\u003c/strong\u003e\u0026nbsp;in an SEC investigation of earnings-related disclosures.\u003c/p\u003e","\u003cp\u003eRepresented the\u0026nbsp;\u003cstrong\u003eindependent directors of a public company\u003c/strong\u003e\u0026nbsp;in connection with an SEC investigation of earnings-related disclosures.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003ethe CEO of a healthcare logistics company\u003c/strong\u003e\u0026nbsp;in SEC and DOJ investigations of the company's disclosures concerning PPE transactions.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003epublic electrical utility\u003c/strong\u003e\u0026nbsp;in an SEC investigation of the utility\u0026rsquo;s historical bond offerings.\u003c/p\u003e","\u003cp\u003eRepresented\u003cstrong\u003e\u0026nbsp;one of the world\u0026rsquo;s largest banks\u003c/strong\u003e\u0026nbsp;in a DOJ investigation concerning the origination and sale of residential mortgage-backed securities during the years leading up to the financial crisis.\u003c/p\u003e","\u003cp\u003eRepresented the\u0026nbsp;\u003cstrong\u003eaudit committee of a public media analytics company\u003c/strong\u003e\u0026nbsp;in an internal investigation and related government investigations into more than 20 separate allegations of accounting fraud and whistleblower retaliation.\u003c/p\u003e","\u003cp\u003eDefended\u003cstrong\u003e\u0026nbsp;a major U.S. law firm and several of its partners and employees\u003c/strong\u003e\u0026nbsp;in an SEC investigation concerning the activities of the firm\u0026rsquo;s former client, an asset manager. The matter was closed without enforcement action.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":175}]},"expertise":[{"id":20,"guid":"20.capabilities","index":0,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":1,"source":"capabilities"},{"id":780,"guid":"780.smart_tags","index":2,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":3,"source":"smartTags"},{"id":27,"guid":"27.capabilities","index":4,"source":"capabilities"},{"id":126,"guid":"126.capabilities","index":5,"source":"capabilities"},{"id":699,"guid":"699.smart_tags","index":6,"source":"smartTags"},{"id":18,"guid":"18.capabilities","index":7,"source":"capabilities"},{"id":111,"guid":"111.capabilities","index":8,"source":"capabilities"},{"id":33,"guid":"33.capabilities","index":9,"source":"capabilities"},{"id":19,"guid":"19.capabilities","index":10,"source":"capabilities"},{"id":127,"guid":"127.capabilities","index":11,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":12,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":13,"source":"capabilities"},{"id":1184,"guid":"1184.smart_tags","index":14,"source":"smartTags"},{"id":1241,"guid":"1241.smart_tags","index":15,"source":"smartTags"},{"id":1261,"guid":"1261.smart_tags","index":16,"source":"smartTags"},{"id":1434,"guid":"1434.smart_tags","index":17,"source":"smartTags"}],"is_active":true,"last_name":"Koch","nick_name":"Alec","clerkships":[],"first_name":"Alec","title_rank":9999,"updated_by":202,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"1997-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Top Ranked Lawyer, Securities: Regulation: Enforcement ","detail":"Chambers USA, Nationwide (2019-PRESENT)"},{"title":"Recognized for \"broad market approval for his enforcement-side practice\" and described as \"an extraordinary lawyer.\"","detail":"Chambers USA, Securities Regulation: Enforcement - USA - Nationwide"}],"linked_in_url":"https://www.linkedin.com/in/alec-koch-75a5412b/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAlec Koch is a co-leader of our Securities Enforcement and Regulation practice and a former Assistant Director with the Securities and Exchange Commission's Division of Enforcement.\u0026nbsp; He represents public companies, financial institutions, boards of directors, and individuals in securities enforcement and anti-corruption investigations before the SEC, DOJ, PCAOB, and other regulatory authorities.\u0026nbsp; Nationally ranked by \u003cem\u003eChambers USA\u003c/em\u003e, Alec is described as having \"broad market approval for his enforcement-side practice.\"\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;Alec also regularly conducts internal investigations on behalf of companies and board committees, often involving multiple jurisdictions,\u0026nbsp;and advises clients on regulatory compliance and corporate governance issues.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAt the SEC, Alec supervised investigations of all types, including matters involving public company accounting and disclosure; The Foreign Corrupt Practices Act; insider trading; regulated entities such as broker-dealers,\u0026nbsp;investment advisers,\u0026nbsp;and credit rating agencies; market manipulation; and securities offerings.\u0026nbsp; He served in multiple leadership roles, including as a member of the Division of Enforcement\u0026rsquo;s Broker-Dealer Task Force, as the co-chair of the Division's\u0026nbsp;Priorities and Resources Subcommittee, and as a liaison\u0026nbsp;between the Division of Enforcement and the SEC\u0026rsquo;s Office of Credit Ratings.\u003c/p\u003e\n\u003cp\u003eAlec\u0026nbsp;serves\u0026nbsp;on the board of directors of Legal Aid D.C.\u0026nbsp;and the Ethics Research Center, a\u0026nbsp;non-profit organization that works to assist public companies and other institutions with building strong ethics and compliance\u0026nbsp;programs.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to working at the\u0026nbsp;SEC, Alec was an associate at King \u0026amp; Spalding from 1997-2002. He rejoined the firm in 2016.\u003c/p\u003e","matters":["\u003cp\u003eRepresenting a\u0026nbsp;\u003cstrong\u003eprovider and operator of compression infrastructure used in the production and transfer of oil and natural gas\u003c/strong\u003e\u0026nbsp;in an investigation related to payments potentially made to Mexican cartels designated as foreign terrorist organizations (FTOs).\u003c/p\u003e","\u003cp\u003eRepresenting the\u0026nbsp;\u003cstrong\u003eaudit committee of a global non-clinical global drug development company\u003c/strong\u003e\u0026nbsp;in an internal investigation related to potential FCPA and disclosure violations.\u003c/p\u003e","\u003cp\u003eRepresenting a\u0026nbsp;\u003cstrong\u003eBig Four accounting firm\u003c/strong\u003e\u0026nbsp;in investigations and securities litigation resulting from the sudden closure of several banks for which the firm acted as external auditor.\u003c/p\u003e","\u003cp\u003eRepresenting the\u0026nbsp;\u003cstrong\u003eCISO of a software development company\u003c/strong\u003e\u0026nbsp;in a first-of-its-kind SEC enforcement action relating to the company's disclosures concerning cybersecurity.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003eprovider of life and health insurance\u003c/strong\u003e\u0026nbsp;in SEC and DOJ investigations related to allegations made by short sellers regarding the company's financial performance and independent agents. The investigations were closed without enforcement action.\u003c/p\u003e","\u003cp\u003eServed as the Independent Compliance Consultant for a\u0026nbsp;\u003cstrong\u003eregistered clearing agency\u003c/strong\u003e\u0026nbsp;in connection with its SEC settlement relating to liquidity arrangements.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003emultinational healthcare company\u003c/strong\u003e\u0026nbsp;in connection with its continuing self-reporting obligations under an FCPA settlement with the DOJ and SEC.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003eglobal manufacturing company\u003c/strong\u003e\u0026nbsp;in an SEC investigation of potential FCPA violations in South America that was closed without enforcement action.\u003c/p\u003e","\u003cp\u003eRepresenting the Audit Committee of\u0026nbsp;\u003cstrong\u003ea space infrastructure development company\u003c/strong\u003e\u0026nbsp;in an independent investigation of accounting and employment allegations raised by a former employee.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003eglobal manufacturing company\u003c/strong\u003e\u0026nbsp;in an SEC investigation concerning air emissions-related issues that was closed without enforcement action.\u003c/p\u003e","\u003cp\u003eRepresented an\u0026nbsp;\u003cstrong\u003einternational chemical company\u0026nbsp;\u003c/strong\u003ein a negotiated resolution of anti-corruption investigations conducted by U.S. and Dutch authorities.\u003c/p\u003e","\u003cp\u003eRepresented the\u0026nbsp;\u003cstrong\u003eaudit committee of a public biopharmaceutical company\u003c/strong\u003e\u0026nbsp;in an internal investigation and related government investigations into allegations of accounting fraud and whistleblower retaliation.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003epublic company provider of services to the healthcare industry\u003c/strong\u003e\u0026nbsp;in an SEC investigation of earnings-related disclosures that was resolved on favorable terms.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003epublic pharmaceutical company\u003c/strong\u003e\u0026nbsp;in an SEC investigation of potential selective disclosures and Reg FD violations that was resolved on favorable terms.\u003c/p\u003e","\u003cp\u003eRepresented the\u003cstrong\u003e\u0026nbsp;independent directors of a commercial flooring company\u003c/strong\u003e\u0026nbsp;in an SEC investigation of earnings-related disclosures.\u003c/p\u003e","\u003cp\u003eRepresented the\u0026nbsp;\u003cstrong\u003eindependent directors of a public company\u003c/strong\u003e\u0026nbsp;in connection with an SEC investigation of earnings-related disclosures.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003ethe CEO of a healthcare logistics company\u003c/strong\u003e\u0026nbsp;in SEC and DOJ investigations of the company's disclosures concerning PPE transactions.\u003c/p\u003e","\u003cp\u003eRepresented a\u0026nbsp;\u003cstrong\u003epublic electrical utility\u003c/strong\u003e\u0026nbsp;in an SEC investigation of the utility\u0026rsquo;s historical bond offerings.\u003c/p\u003e","\u003cp\u003eRepresented\u003cstrong\u003e\u0026nbsp;one of the world\u0026rsquo;s largest banks\u003c/strong\u003e\u0026nbsp;in a DOJ investigation concerning the origination and sale of residential mortgage-backed securities during the years leading up to the financial crisis.\u003c/p\u003e","\u003cp\u003eRepresented the\u0026nbsp;\u003cstrong\u003eaudit committee of a public media analytics company\u003c/strong\u003e\u0026nbsp;in an internal investigation and related government investigations into more than 20 separate allegations of accounting fraud and whistleblower retaliation.\u003c/p\u003e","\u003cp\u003eDefended\u003cstrong\u003e\u0026nbsp;a major U.S. law firm and several of its partners and employees\u003c/strong\u003e\u0026nbsp;in an SEC investigation concerning the activities of the firm\u0026rsquo;s former client, an asset manager. The matter was closed without enforcement action.\u003c/p\u003e"],"recognitions":[{"title":"Top Ranked Lawyer, Securities: Regulation: Enforcement ","detail":"Chambers USA, Nationwide (2019-PRESENT)"},{"title":"Recognized for \"broad market approval for his enforcement-side practice\" and described as \"an extraordinary lawyer.\"","detail":"Chambers USA, Securities Regulation: Enforcement - USA - Nationwide"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9976}]},"capability_group_id":2},"created_at":"2025-10-21T18:47:33.000Z","updated_at":"2025-10-21T18:47:33.000Z","searchable_text":"Koch{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, Securities: Regulation: Enforcement \", :detail=\u0026gt;\"Chambers USA, Nationwide (2019-PRESENT)\"}{{ FIELD }}{:title=\u0026gt;\"Recognized for \\\"broad market approval for his enforcement-side practice\\\" and described as \\\"an extraordinary lawyer.\\\"\", :detail=\u0026gt;\"Chambers USA, Securities Regulation: Enforcement - USA - Nationwide\"}{{ FIELD }}Representing a provider and operator of compression infrastructure used in the production and transfer of oil and natural gas in an investigation related to payments potentially made to Mexican cartels designated as foreign terrorist organizations (FTOs).{{ FIELD }}Representing the audit committee of a global non-clinical global drug development company in an internal investigation related to potential FCPA and disclosure violations.{{ FIELD }}Representing a Big Four accounting firm in investigations and securities litigation resulting from the sudden closure of several banks for which the firm acted as external auditor.{{ FIELD }}Representing the CISO of a software development company in a first-of-its-kind SEC enforcement action relating to the company's disclosures concerning cybersecurity.{{ FIELD }}Represented a provider of life and health insurance in SEC and DOJ investigations related to allegations made by short sellers regarding the company's financial performance and independent agents. The investigations were closed without enforcement action.{{ FIELD }}Served as the Independent Compliance Consultant for a registered clearing agency in connection with its SEC settlement relating to liquidity arrangements.{{ FIELD }}Represented a multinational healthcare company in connection with its continuing self-reporting obligations under an FCPA settlement with the DOJ and SEC.{{ FIELD }}Represented a global manufacturing company in an SEC investigation of potential FCPA violations in South America that was closed without enforcement action.{{ FIELD }}Representing the Audit Committee of a space infrastructure development company in an independent investigation of accounting and employment allegations raised by a former employee.{{ FIELD }}Represented a global manufacturing company in an SEC investigation concerning air emissions-related issues that was closed without enforcement action.{{ FIELD }}Represented an international chemical company in a negotiated resolution of anti-corruption investigations conducted by U.S. and Dutch authorities.{{ FIELD }}Represented the audit committee of a public biopharmaceutical company in an internal investigation and related government investigations into allegations of accounting fraud and whistleblower retaliation.{{ FIELD }}Represented a public company provider of services to the healthcare industry in an SEC investigation of earnings-related disclosures that was resolved on favorable terms.{{ FIELD }}Represented a public pharmaceutical company in an SEC investigation of potential selective disclosures and Reg FD violations that was resolved on favorable terms.{{ FIELD }}Represented the independent directors of a commercial flooring company in an SEC investigation of earnings-related disclosures.{{ FIELD }}Represented the independent directors of a public company in connection with an SEC investigation of earnings-related disclosures.{{ FIELD }}Represented the CEO of a healthcare logistics company in SEC and DOJ investigations of the company's disclosures concerning PPE transactions.{{ FIELD }}Represented a public electrical utility in an SEC investigation of the utility’s historical bond offerings.{{ FIELD }}Represented one of the world’s largest banks in a DOJ investigation concerning the origination and sale of residential mortgage-backed securities during the years leading up to the financial crisis.{{ FIELD }}Represented the audit committee of a public media analytics company in an internal investigation and related government investigations into more than 20 separate allegations of accounting fraud and whistleblower retaliation.{{ FIELD }}Defended a major U.S. law firm and several of its partners and employees in an SEC investigation concerning the activities of the firm’s former client, an asset manager. The matter was closed without enforcement action.{{ FIELD }}Alec Koch is a co-leader of our Securities Enforcement and Regulation practice and a former Assistant Director with the Securities and Exchange Commission's Division of Enforcement.  He represents public companies, financial institutions, boards of directors, and individuals in securities enforcement and anti-corruption investigations before the SEC, DOJ, PCAOB, and other regulatory authorities.  Nationally ranked by Chambers USA, Alec is described as having \"broad market approval for his enforcement-side practice.\"\n Alec also regularly conducts internal investigations on behalf of companies and board committees, often involving multiple jurisdictions, and advises clients on regulatory compliance and corporate governance issues. \nAt the SEC, Alec supervised investigations of all types, including matters involving public company accounting and disclosure; The Foreign Corrupt Practices Act; insider trading; regulated entities such as broker-dealers, investment advisers, and credit rating agencies; market manipulation; and securities offerings.  He served in multiple leadership roles, including as a member of the Division of Enforcement’s Broker-Dealer Task Force, as the co-chair of the Division's Priorities and Resources Subcommittee, and as a liaison between the Division of Enforcement and the SEC’s Office of Credit Ratings.\nAlec serves on the board of directors of Legal Aid D.C. and the Ethics Research Center, a non-profit organization that works to assist public companies and other institutions with building strong ethics and compliance programs.  \nPrior to working at the SEC, Alec was an associate at King \u0026amp; Spalding from 1997-2002. He rejoined the firm in 2016. M Alexander Koch Partner Top Ranked Lawyer, Securities: Regulation: Enforcement  Chambers USA, Nationwide (2019-PRESENT) Recognized for \"broad market approval for his enforcement-side practice\" and described as \"an extraordinary lawyer.\" Chambers USA, Securities Regulation: Enforcement - USA - Nationwide University of Virginia University of Virginia School of Law Georgetown University Georgetown University Law Center District of Columbia Representing a provider and operator of compression infrastructure used in the production and transfer of oil and natural gas in an investigation related to payments potentially made to Mexican cartels designated as foreign terrorist organizations (FTOs). Representing the audit committee of a global non-clinical global drug development company in an internal investigation related to potential FCPA and disclosure violations. Representing a Big Four accounting firm in investigations and securities litigation resulting from the sudden closure of several banks for which the firm acted as external auditor. Representing the CISO of a software development company in a first-of-its-kind SEC enforcement action relating to the company's disclosures concerning cybersecurity. Represented a provider of life and health insurance in SEC and DOJ investigations related to allegations made by short sellers regarding the company's financial performance and independent agents. The investigations were closed without enforcement action. Served as the Independent Compliance Consultant for a registered clearing agency in connection with its SEC settlement relating to liquidity arrangements. Represented a multinational healthcare company in connection with its continuing self-reporting obligations under an FCPA settlement with the DOJ and SEC. Represented a global manufacturing company in an SEC investigation of potential FCPA violations in South America that was closed without enforcement action. Representing the Audit Committee of a space infrastructure development company in an independent investigation of accounting and employment allegations raised by a former employee. Represented a global manufacturing company in an SEC investigation concerning air emissions-related issues that was closed without enforcement action. Represented an international chemical company in a negotiated resolution of anti-corruption investigations conducted by U.S. and Dutch authorities. Represented the audit committee of a public biopharmaceutical company in an internal investigation and related government investigations into allegations of accounting fraud and whistleblower retaliation. Represented a public company provider of services to the healthcare industry in an SEC investigation of earnings-related disclosures that was resolved on favorable terms. Represented a public pharmaceutical company in an SEC investigation of potential selective disclosures and Reg FD violations that was resolved on favorable terms. Represented the independent directors of a commercial flooring company in an SEC investigation of earnings-related disclosures. Represented the independent directors of a public company in connection with an SEC investigation of earnings-related disclosures. Represented the CEO of a healthcare logistics company in SEC and DOJ investigations of the company's disclosures concerning PPE transactions. Represented a public electrical utility in an SEC investigation of the utility’s historical bond offerings. Represented one of the world’s largest banks in a DOJ investigation concerning the origination and sale of residential mortgage-backed securities during the years leading up to the financial crisis. Represented the audit committee of a public media analytics company in an internal investigation and related government investigations into more than 20 separate allegations of accounting fraud and whistleblower retaliation. Defended a major U.S. law firm and several of its partners and employees in an SEC investigation concerning the activities of the firm’s former client, an asset manager. The matter was closed without enforcement action.","searchable_name":"Alec Koch","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":447847,"version":1,"owner_type":"Person","owner_id":3966,"payload":{"bio":"\u003cp\u003eYelena is a partner in the Special Matters and Investigations practice in the New York office of King \u0026amp; Spalding. Yelena focuses on white-collar criminal defense litigation, internal and government investigations, corporate compliance, congressional investigations and regulatory matters. Yelena has represented corporations and individuals in a wide array of matters, including the False Claims Act; the Anti-Kickback Statute; the Foreign Corrupt Practices Act, and criminal sanctions. She works with clients facing government investigations conducted by various divisions of the Department of Justice, the U.S. Attorneys' Offices, the Securities and Exchange Commission, and various state agencies and state attorneys general.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eYelena received her J.D. (\u003cem\u003ecum laude\u003c/em\u003e) from Fordham University School of Law in 2013, where she served as Articles and Notes Editor of the Fordham Law Review, and as Associate Editor on the Fordham Moot Court Board. While at Fordham, Ms. Kotlarsky served as a summer intern for the Hon. Sherry Klein Heitler, Administrative Judge, Supreme Court, New York County. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026ldquo;SEC Behind Times in 'Modernizing' Administrative Proceedings,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Law Journal\u003c/em\u003e\u0026nbsp;(November 2015)\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;R (AL) v Serious Fraud Office: further divergence between UK and US investigations practice on the horizon,\u0026rdquo;\u0026nbsp;\u003cem\u003eThomson Reuters Practical Law UK\u003c/em\u003e\u0026nbsp;(May 2018)\u003c/li\u003e\n\u003c/ul\u003e","slug":"yelena-kotlarsky","email":"ykotlarsky@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresenting technology company in litigation alleging economic damages arising from adolescent use of various online communications services.\u003c/p\u003e","\u003cp\u003eRepresenting multinational private equity firm in successful defense against False Claims Act allegations, resulting in a DOJ declination and a complete dismissal of a subsequent \u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;FCA action.\u003c/p\u003e","\u003cp\u003eRepresenting a founder and former chief executive and chairman in a criminal insider trading case.\u003c/p\u003e","\u003cp\u003eRepresenting a global medical device manufacturer in an investigation based on allegations of Anti-Kickback Statute violations.\u003c/p\u003e","\u003cp\u003eAdvising a pharmaceutical company in a DOJ False Claims Act investigation.\u003c/p\u003e","\u003cp\u003eConducting an internal investigation on behalf of a major Turkish bank in connection with allegations of money laundering and sanctions violations.\u003c/p\u003e","\u003cp\u003eRepresented an SEC-registered credit rating agency in connection with industry-wide investigations being conducted by the SEC and the New York Attorney General concerning potential ratings shopping.\u003c/p\u003e","\u003cp\u003ePerforming internal compliance reviews and anticorruption analysis for a global insurance broker.\u003c/p\u003e","\u003cp\u003eAdvising an international oil and gas company on compliance issues related to overseas projects.\u003c/p\u003e","\u003cp\u003eRepresenting a professional sports team owner in connection with an investigation by the Securities and Exchange Commission.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":2,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":3,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":4,"source":"smartTags"},{"id":973,"guid":"973.smart_tags","index":5,"source":"smartTags"},{"id":113,"guid":"113.capabilities","index":6,"source":"capabilities"},{"id":1188,"guid":"1188.smart_tags","index":7,"source":"smartTags"},{"id":1248,"guid":"1248.smart_tags","index":8,"source":"smartTags"},{"id":1434,"guid":"1434.smart_tags","index":9,"source":"smartTags"}],"is_active":true,"last_name":"Kotlarsky","nick_name":"Yelena","clerkships":[],"first_name":"Yelena","title_rank":9999,"updated_by":202,"law_schools":[{"id":722,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2013-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eYelena is a partner in the Special Matters and Investigations practice in the New York office of King \u0026amp; Spalding. Yelena focuses on white-collar criminal defense litigation, internal and government investigations, corporate compliance, congressional investigations and regulatory matters. Yelena has represented corporations and individuals in a wide array of matters, including the False Claims Act; the Anti-Kickback Statute; the Foreign Corrupt Practices Act, and criminal sanctions. She works with clients facing government investigations conducted by various divisions of the Department of Justice, the U.S. Attorneys' Offices, the Securities and Exchange Commission, and various state agencies and state attorneys general.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eYelena received her J.D. (\u003cem\u003ecum laude\u003c/em\u003e) from Fordham University School of Law in 2013, where she served as Articles and Notes Editor of the Fordham Law Review, and as Associate Editor on the Fordham Moot Court Board. While at Fordham, Ms. Kotlarsky served as a summer intern for the Hon. Sherry Klein Heitler, Administrative Judge, Supreme Court, New York County. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026ldquo;SEC Behind Times in 'Modernizing' Administrative Proceedings,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Law Journal\u003c/em\u003e\u0026nbsp;(November 2015)\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;R (AL) v Serious Fraud Office: further divergence between UK and US investigations practice on the horizon,\u0026rdquo;\u0026nbsp;\u003cem\u003eThomson Reuters Practical Law UK\u003c/em\u003e\u0026nbsp;(May 2018)\u003c/li\u003e\n\u003c/ul\u003e","matters":["\u003cp\u003eRepresenting technology company in litigation alleging economic damages arising from adolescent use of various online communications services.\u003c/p\u003e","\u003cp\u003eRepresenting multinational private equity firm in successful defense against False Claims Act allegations, resulting in a DOJ declination and a complete dismissal of a subsequent \u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;FCA action.\u003c/p\u003e","\u003cp\u003eRepresenting a founder and former chief executive and chairman in a criminal insider trading case.\u003c/p\u003e","\u003cp\u003eRepresenting a global medical device manufacturer in an investigation based on allegations of Anti-Kickback Statute violations.\u003c/p\u003e","\u003cp\u003eAdvising a pharmaceutical company in a DOJ False Claims Act investigation.\u003c/p\u003e","\u003cp\u003eConducting an internal investigation on behalf of a major Turkish bank in connection with allegations of money laundering and sanctions violations.\u003c/p\u003e","\u003cp\u003eRepresented an SEC-registered credit rating agency in connection with industry-wide investigations being conducted by the SEC and the New York Attorney General concerning potential ratings shopping.\u003c/p\u003e","\u003cp\u003ePerforming internal compliance reviews and anticorruption analysis for a global insurance broker.\u003c/p\u003e","\u003cp\u003eAdvising an international oil and gas company on compliance issues related to overseas projects.\u003c/p\u003e","\u003cp\u003eRepresenting a professional sports team owner in connection with an investigation by the Securities and Exchange Commission.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":58}]},"capability_group_id":2},"created_at":"2026-04-27T15:48:47.000Z","updated_at":"2026-04-27T15:48:47.000Z","searchable_text":"Kotlarsky{{ FIELD }}Representing technology company in litigation alleging economic damages arising from adolescent use of various online communications services.{{ FIELD }}Representing multinational private equity firm in successful defense against False Claims Act allegations, resulting in a DOJ declination and a complete dismissal of a subsequent qui tam FCA action.{{ FIELD }}Representing a founder and former chief executive and chairman in a criminal insider trading case.{{ FIELD }}Representing a global medical device manufacturer in an investigation based on allegations of Anti-Kickback Statute violations.{{ FIELD }}Advising a pharmaceutical company in a DOJ False Claims Act investigation.{{ FIELD }}Conducting an internal investigation on behalf of a major Turkish bank in connection with allegations of money laundering and sanctions violations.{{ FIELD }}Represented an SEC-registered credit rating agency in connection with industry-wide investigations being conducted by the SEC and the New York Attorney General concerning potential ratings shopping.{{ FIELD }}Performing internal compliance reviews and anticorruption analysis for a global insurance broker.{{ FIELD }}Advising an international oil and gas company on compliance issues related to overseas projects.{{ FIELD }}Representing a professional sports team owner in connection with an investigation by the Securities and Exchange Commission.{{ FIELD }}Yelena is a partner in the Special Matters and Investigations practice in the New York office of King \u0026amp; Spalding. Yelena focuses on white-collar criminal defense litigation, internal and government investigations, corporate compliance, congressional investigations and regulatory matters. Yelena has represented corporations and individuals in a wide array of matters, including the False Claims Act; the Anti-Kickback Statute; the Foreign Corrupt Practices Act, and criminal sanctions. She works with clients facing government investigations conducted by various divisions of the Department of Justice, the U.S. Attorneys' Offices, the Securities and Exchange Commission, and various state agencies and state attorneys general.\nYelena received her J.D. (cum laude) from Fordham University School of Law in 2013, where she served as Articles and Notes Editor of the Fordham Law Review, and as Associate Editor on the Fordham Moot Court Board. While at Fordham, Ms. Kotlarsky served as a summer intern for the Hon. Sherry Klein Heitler, Administrative Judge, Supreme Court, New York County.  \nPublications\n\n“SEC Behind Times in 'Modernizing' Administrative Proceedings,” New York Law Journal (November 2015)\n“R (AL) v Serious Fraud Office: further divergence between UK and US investigations practice on the horizon,” Thomson Reuters Practical Law UK (May 2018)\n Partner Cornell University Cornell Law School Fordham University Fordham University School of Law U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York New York Representing technology company in litigation alleging economic damages arising from adolescent use of various online communications services. Representing multinational private equity firm in successful defense against False Claims Act allegations, resulting in a DOJ declination and a complete dismissal of a subsequent qui tam FCA action. Representing a founder and former chief executive and chairman in a criminal insider trading case. Representing a global medical device manufacturer in an investigation based on allegations of Anti-Kickback Statute violations. Advising a pharmaceutical company in a DOJ False Claims Act investigation. Conducting an internal investigation on behalf of a major Turkish bank in connection with allegations of money laundering and sanctions violations. Represented an SEC-registered credit rating agency in connection with industry-wide investigations being conducted by the SEC and the New York Attorney General concerning potential ratings shopping. Performing internal compliance reviews and anticorruption analysis for a global insurance broker. Advising an international oil and gas company on compliance issues related to overseas projects. Representing a professional sports team owner in connection with an investigation by the Securities and Exchange Commission.","searchable_name":"Yelena Kotlarsky","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426774,"version":1,"owner_type":"Person","owner_id":5576,"payload":{"bio":"\u003cp\u003eNicholas\u0026rsquo;s practice focuses on corporate internal investigations, defense of corporations and individuals in government investigations, white-collar criminal defense, and related complex civil litigation in state and federal court.\u0026nbsp; His experience includes defending companies and individuals in investigations and enforcement actions by various House and Senate committees, the Department of Justice, the U.S. Securities and Exchange Commission (SEC), Public Company Accounting Oversight Board (PCAOB), the Internal Revenue Service (IRS), state attorneys general, and other federal, state, and local agencies.\u0026nbsp; He has experience across a range of industries, including financial services, consumer retail, higher education, technology, healthcare, and life sciences.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNicholas\u0026rsquo;s mix of white-collar and civil experience enables him to coordinate cohesive responses for clients facing multiple investigatory, litigation, and public relations issues that often arise in crisis or bet-the-company situations.\u0026nbsp; In addition, Nicholas provides compliance, risk-assessment, and crisis-management advice to companies.\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Nicholas worked in another global law firm's state and local tax practice where he advised clients in all stages of tax controversy beginning at audit all the way through litigation and appeal.\u0026nbsp; His multi-state tax experience includes resolving controversies involving corporate income, sales and use, gross receipts, and property tax matters.\u003c/p\u003e","slug":"nicholas-kump","email":"nkump@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":37,"guid":"37.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":3,"source":"smartTags"},{"id":18,"guid":"18.capabilities","index":4,"source":"capabilities"},{"id":1153,"guid":"1153.smart_tags","index":5,"source":"smartTags"},{"id":1241,"guid":"1241.smart_tags","index":6,"source":"smartTags"},{"id":109,"guid":"109.capabilities","index":7,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":10,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":11,"source":"capabilities"},{"id":1261,"guid":"1261.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Kump","nick_name":"Nicholas","clerkships":[{"name":"Judicial Clerk, Sheila K. Oberto, U.S. District Court for the Eastern District of California","years_held":"2018 - 2019"}],"first_name":"Nicholas","title_rank":9999,"updated_by":35,"law_schools":[{"id":2402,"meta":{"degree":"J.D.","honors":"Order of the Coif, First in Class","is_law_school":1,"graduation_date":null},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"J.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eNicholas\u0026rsquo;s practice focuses on corporate internal investigations, defense of corporations and individuals in government investigations, white-collar criminal defense, and related complex civil litigation in state and federal court.\u0026nbsp; His experience includes defending companies and individuals in investigations and enforcement actions by various House and Senate committees, the Department of Justice, the U.S. Securities and Exchange Commission (SEC), Public Company Accounting Oversight Board (PCAOB), the Internal Revenue Service (IRS), state attorneys general, and other federal, state, and local agencies.\u0026nbsp; He has experience across a range of industries, including financial services, consumer retail, higher education, technology, healthcare, and life sciences.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNicholas\u0026rsquo;s mix of white-collar and civil experience enables him to coordinate cohesive responses for clients facing multiple investigatory, litigation, and public relations issues that often arise in crisis or bet-the-company situations.\u0026nbsp; In addition, Nicholas provides compliance, risk-assessment, and crisis-management advice to companies.\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Nicholas worked in another global law firm's state and local tax practice where he advised clients in all stages of tax controversy beginning at audit all the way through litigation and appeal.\u0026nbsp; His multi-state tax experience includes resolving controversies involving corporate income, sales and use, gross receipts, and property tax matters.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":7102}]},"capability_group_id":2},"created_at":"2025-05-26T04:56:42.000Z","updated_at":"2025-05-26T04:56:42.000Z","searchable_text":"Kump{{ FIELD }}Nicholas’s practice focuses on corporate internal investigations, defense of corporations and individuals in government investigations, white-collar criminal defense, and related complex civil litigation in state and federal court.  His experience includes defending companies and individuals in investigations and enforcement actions by various House and Senate committees, the Department of Justice, the U.S. Securities and Exchange Commission (SEC), Public Company Accounting Oversight Board (PCAOB), the Internal Revenue Service (IRS), state attorneys general, and other federal, state, and local agencies.  He has experience across a range of industries, including financial services, consumer retail, higher education, technology, healthcare, and life sciences.\nNicholas’s mix of white-collar and civil experience enables him to coordinate cohesive responses for clients facing multiple investigatory, litigation, and public relations issues that often arise in crisis or bet-the-company situations.  In addition, Nicholas provides compliance, risk-assessment, and crisis-management advice to companies.\nPrior to joining King \u0026amp; Spalding, Nicholas worked in another global law firm's state and local tax practice where he advised clients in all stages of tax controversy beginning at audit all the way through litigation and appeal.  His multi-state tax experience includes resolving controversies involving corporate income, sales and use, gross receipts, and property tax matters. Senior Associate University of Southern California USC Gould School of Law University of the Pacific McGeorge School of Law California Judicial Clerk, Sheila K. Oberto, U.S. District Court for the Eastern District of California","searchable_name":"Nicholas J. Kump","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":432495,"version":1,"owner_type":"Person","owner_id":6494,"payload":{"bio":"\u003cp\u003ePeter\u0026nbsp;Kim is an associate in the Special Matters \u0026amp; Government Investigations practice\u0026nbsp;in King \u0026amp; Spalding's New York office. Peter helps clients navigate through\u0026nbsp;a broad range of complex disputes in response to significant cross-border risk, in addition to government regulatory matters, corporate internal investigations, and related civil litigation.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePeter specializes in representing companies in complex international\u0026nbsp;disputes involving\u0026nbsp;multiple jurisdictions around the world. He\u0026nbsp;provides clients with comprehensive\u0026nbsp;global litigation strategy, crisis management, and risk mitigation advice.\u003c/p\u003e\n\u003cp\u003eAdditionally, Peter\u0026nbsp;advises companies in connection with government regulatory and corporate internal investigations and has represented clients\u0026nbsp;in investigations and litigation brought by the DOJ, State AGs, and other agencies.\u003c/p\u003e\n\u003cp\u003ePeter received his J.D. from Columbia Law School, where he was\u0026nbsp;a Harlan Fiske Stone Scholar and a recipient of the Parker School Certificate for Achievement in International and Comparative Law. At Columbia, Peter served as\u0026nbsp;Executive Editor of the \u003cem\u003eColumbia Journal of Transnational Law\u003c/em\u003e.\u0026nbsp;He received his\u0026nbsp;M.A. from the Johns Hopkins School of Advanced International Studies and his B.A. from Columbia University. Prior to joining King \u0026amp; Spalding, Peter practiced in the New York office of Freshfields Bruckhaus Deringer.\u003c/p\u003e\n\u003cp\u003ePeter is admitted to practice in New York.\u003c/p\u003e","slug":"peter-kim","email":"pkim@kslaw.com","phone":null,"matters":["\u003cp\u003eAdvising and representing\u0026nbsp;\u003cstrong\u003emajor global technology companies\u003c/strong\u003e\u0026nbsp;with global litigation and risk mitigation strategy across multiple jurisdictions in matters relating to Russia and the international response to the Russia-Ukraine conflict.\u003c/p\u003e","\u003cp\u003eAdvising a\u0026nbsp;\u003cstrong\u003emajor global technology company\u003c/strong\u003e\u0026nbsp;on multiple internal investigations.\u003c/p\u003e","\u003cp\u003eAdvising a\u0026nbsp;\u003cstrong\u003emajor global technology company\u003c/strong\u003e\u0026nbsp;on key strategic regulatory risks.\u003c/p\u003e","\u003cp\u003eAdvising a\u0026nbsp;\u003cstrong\u003emajor global technology company\u003c/strong\u003e\u0026nbsp;on referrals to law enforcement in issues involving trade secret exfiltration.\u003c/p\u003e","\u003cp\u003eAdvising and representing\u0026nbsp;\u003cstrong\u003emultiple\u003c/strong\u003e\u0026nbsp;\u003cstrong\u003emajor corporate clients\u003c/strong\u003e\u0026nbsp;in civil litigation and commercial and investment arbitration under the AAA, ICC, JAMS, and UNCITRAL rules in high-stakes breach-of-contract, post-M\u0026amp;A, construction, and investment treaty disputes.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3249}]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":14,"guid":"14.capabilities","index":1,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":128,"guid":"128.capabilities","index":4,"source":"capabilities"},{"id":111,"guid":"111.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"}],"is_active":true,"last_name":"Kim","nick_name":"Peter","clerkships":[],"first_name":"Peter","title_rank":9999,"updated_by":202,"law_schools":[{"id":485,"meta":{"degree":"J.D.","honors":"Harlan Fiske Stone Scholar","is_law_school":"1","graduation_date":null},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"C. Y.","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/petercykim/","seodescription":"Peter Kim is an associate in the Special Matters \u0026 Government Investigations practice in King \u0026 Spalding's New York office. Read more about him.","primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003ePeter\u0026nbsp;Kim is an associate in the Special Matters \u0026amp; Government Investigations practice\u0026nbsp;in King \u0026amp; Spalding's New York office. Peter helps clients navigate through\u0026nbsp;a broad range of complex disputes in response to significant cross-border risk, in addition to government regulatory matters, corporate internal investigations, and related civil litigation.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePeter specializes in representing companies in complex international\u0026nbsp;disputes involving\u0026nbsp;multiple jurisdictions around the world. He\u0026nbsp;provides clients with comprehensive\u0026nbsp;global litigation strategy, crisis management, and risk mitigation advice.\u003c/p\u003e\n\u003cp\u003eAdditionally, Peter\u0026nbsp;advises companies in connection with government regulatory and corporate internal investigations and has represented clients\u0026nbsp;in investigations and litigation brought by the DOJ, State AGs, and other agencies.\u003c/p\u003e\n\u003cp\u003ePeter received his J.D. from Columbia Law School, where he was\u0026nbsp;a Harlan Fiske Stone Scholar and a recipient of the Parker School Certificate for Achievement in International and Comparative Law. At Columbia, Peter served as\u0026nbsp;Executive Editor of the \u003cem\u003eColumbia Journal of Transnational Law\u003c/em\u003e.\u0026nbsp;He received his\u0026nbsp;M.A. from the Johns Hopkins School of Advanced International Studies and his B.A. from Columbia University. Prior to joining King \u0026amp; Spalding, Peter practiced in the New York office of Freshfields Bruckhaus Deringer.\u003c/p\u003e\n\u003cp\u003ePeter is admitted to practice in New York.\u003c/p\u003e","matters":["\u003cp\u003eAdvising and representing\u0026nbsp;\u003cstrong\u003emajor global technology companies\u003c/strong\u003e\u0026nbsp;with global litigation and risk mitigation strategy across multiple jurisdictions in matters relating to Russia and the international response to the Russia-Ukraine conflict.\u003c/p\u003e","\u003cp\u003eAdvising a\u0026nbsp;\u003cstrong\u003emajor global technology company\u003c/strong\u003e\u0026nbsp;on multiple internal investigations.\u003c/p\u003e","\u003cp\u003eAdvising a\u0026nbsp;\u003cstrong\u003emajor global technology company\u003c/strong\u003e\u0026nbsp;on key strategic regulatory risks.\u003c/p\u003e","\u003cp\u003eAdvising a\u0026nbsp;\u003cstrong\u003emajor global technology company\u003c/strong\u003e\u0026nbsp;on referrals to law enforcement in issues involving trade secret exfiltration.\u003c/p\u003e","\u003cp\u003eAdvising and representing\u0026nbsp;\u003cstrong\u003emultiple\u003c/strong\u003e\u0026nbsp;\u003cstrong\u003emajor corporate clients\u003c/strong\u003e\u0026nbsp;in civil litigation and commercial and investment arbitration under the AAA, ICC, JAMS, and UNCITRAL rules in high-stakes breach-of-contract, post-M\u0026amp;A, construction, and investment treaty disputes.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10553}]},"capability_group_id":2},"created_at":"2025-07-25T13:54:48.000Z","updated_at":"2025-07-25T13:54:48.000Z","searchable_text":"Kim{{ FIELD }}Advising and representing major global technology companies with global litigation and risk mitigation strategy across multiple jurisdictions in matters relating to Russia and the international response to the Russia-Ukraine conflict.{{ FIELD }}Advising a major global technology company on multiple internal investigations.{{ FIELD }}Advising a major global technology company on key strategic regulatory risks.{{ FIELD }}Advising a major global technology company on referrals to law enforcement in issues involving trade secret exfiltration.{{ FIELD }}Advising and representing multiple major corporate clients in civil litigation and commercial and investment arbitration under the AAA, ICC, JAMS, and UNCITRAL rules in high-stakes breach-of-contract, post-M\u0026amp;A, construction, and investment treaty disputes.{{ FIELD }}Peter Kim is an associate in the Special Matters \u0026amp; Government Investigations practice in King \u0026amp; Spalding's New York office. Peter helps clients navigate through a broad range of complex disputes in response to significant cross-border risk, in addition to government regulatory matters, corporate internal investigations, and related civil litigation. \nPeter specializes in representing companies in complex international disputes involving multiple jurisdictions around the world. He provides clients with comprehensive global litigation strategy, crisis management, and risk mitigation advice.\nAdditionally, Peter advises companies in connection with government regulatory and corporate internal investigations and has represented clients in investigations and litigation brought by the DOJ, State AGs, and other agencies.\nPeter received his J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar and a recipient of the Parker School Certificate for Achievement in International and Comparative Law. At Columbia, Peter served as Executive Editor of the Columbia Journal of Transnational Law. He received his M.A. from the Johns Hopkins School of Advanced International Studies and his B.A. from Columbia University. Prior to joining King \u0026amp; Spalding, Peter practiced in the New York office of Freshfields Bruckhaus Deringer.\nPeter is admitted to practice in New York. Peter Kim lawyer Associate Columbia University Columbia University Columbia University Columbia University School of Law Johns Hopkins University  New York Advising and representing major global technology companies with global litigation and risk mitigation strategy across multiple jurisdictions in matters relating to Russia and the international response to the Russia-Ukraine conflict. Advising a major global technology company on multiple internal investigations. Advising a major global technology company on key strategic regulatory risks. Advising a major global technology company on referrals to law enforcement in issues involving trade secret exfiltration. Advising and representing multiple major corporate clients in civil litigation and commercial and investment arbitration under the AAA, ICC, JAMS, and UNCITRAL rules in high-stakes breach-of-contract, post-M\u0026amp;A, construction, and investment treaty disputes.","searchable_name":"Peter C. Y. Kim","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":427259,"version":1,"owner_type":"Person","owner_id":6562,"payload":{"bio":"\u003cp\u003eIsabel is an associate in the Special Matters \u0026amp; Government Investigations group in King \u0026amp; Spalding's Chicago office. Her practice focuses on government investigations, white-collar criminal defense, and related civil litigation.\u0026nbsp;\u003c/p\u003e","slug":"isabel-king","email":"iking@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"}],"is_active":true,"last_name":"King","nick_name":"Isabel","clerkships":[],"first_name":"Isabel","title_rank":9999,"updated_by":202,"law_schools":[{"id":1451,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":1,"graduation_date":"2024-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003eIsabel is an associate in the Special Matters \u0026amp; Government Investigations group in King \u0026amp; Spalding's Chicago office. Her practice focuses on government investigations, white-collar criminal defense, and related civil litigation.\u0026nbsp;\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12254}]},"capability_group_id":2},"created_at":"2025-05-26T04:59:28.000Z","updated_at":"2025-05-26T04:59:28.000Z","searchable_text":"King{{ FIELD }}Isabel is an associate in the Special Matters \u0026amp; Government Investigations group in King \u0026amp; Spalding's Chicago office. Her practice focuses on government investigations, white-collar criminal defense, and related civil litigation.  Associate University of Wisconsin-Madison University of Wisconsin Law School Northwestern University Northwestern Pritzker School of Law","searchable_name":"Isabel King","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":436447,"version":1,"owner_type":"Person","owner_id":5785,"payload":{"bio":"\u003cp\u003eLauren's practice focuses on securities enforcement, anti-corruption\u0026nbsp;investigations, internal investigations, compliance counseling,\u0026nbsp;white-collar criminal defense, and related civil litigation.\u0026nbsp;Lauren represents\u0026nbsp;clients\u0026nbsp;before the U.S. Securities and Exchange Commission and U.S. Department of Justice, as well as other domestic and international authorities.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eLauren graduated from the Georgetown University Law Center\u0026nbsp;and earned her M.A. and B.A. from the George Washington University. During law school, she was a Managing Editor for the\u0026nbsp;\u003cem\u003eAmerican Criminal Law Review\u003c/em\u003e,\u0026nbsp;a member of the Appellate Advocacy Division of Barristers' Council, and a student attorney for the International Women's Human Rights Clinic.\u003c/p\u003e\n\u003cp\u003eLauren has interned for the Division of Enforcement and Division of Examinations at the U.S. Securities and Exchange Commission, the Money Laundering and Asset Recovery Section at the U.S. Department of Justice, the U.S. Attorney's Office for the District of Maryland, the Honorable Timothy J. Kelly, and the Office of General Counsel at\u0026nbsp;the National Archives and Records Administration.\u003c/p\u003e","slug":"lauren-konczos","email":"lkonczos@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":20,"guid":"20.capabilities","index":0,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":126,"guid":"126.capabilities","index":3,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":4,"source":"capabilities"},{"id":1188,"guid":"1188.smart_tags","index":5,"source":"smartTags"},{"id":766,"guid":"766.smart_tags","index":6,"source":"smartTags"},{"id":1199,"guid":"1199.smart_tags","index":7,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":8,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":9,"source":"smartTags"},{"id":923,"guid":"923.smart_tags","index":10,"source":"smartTags"},{"id":1184,"guid":"1184.smart_tags","index":11,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":12,"source":"smartTags"},{"id":5,"guid":"5.smart_tags","index":13,"source":"smartTags"}],"is_active":true,"last_name":"Konczos","nick_name":"Lauren","clerkships":[{"name":"Intern, The Honorable Timothy J. Kelly, U.S. District Court for the District of Columbia","years_held":"2020 - 2020"}],"first_name":"Lauren","title_rank":9999,"updated_by":101,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2021-01-01 00:00:00 UTC"},"order":2,"pin_order":null,"pin_expiration":null}],"middle_name":"O.","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/laurenkonczos/","seodescription":null,"primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003eLauren's practice focuses on securities enforcement, anti-corruption\u0026nbsp;investigations, internal investigations, compliance counseling,\u0026nbsp;white-collar criminal defense, and related civil litigation.\u0026nbsp;Lauren represents\u0026nbsp;clients\u0026nbsp;before the U.S. Securities and Exchange Commission and U.S. Department of Justice, as well as other domestic and international authorities.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eLauren graduated from the Georgetown University Law Center\u0026nbsp;and earned her M.A. and B.A. from the George Washington University. During law school, she was a Managing Editor for the\u0026nbsp;\u003cem\u003eAmerican Criminal Law Review\u003c/em\u003e,\u0026nbsp;a member of the Appellate Advocacy Division of Barristers' Council, and a student attorney for the International Women's Human Rights Clinic.\u003c/p\u003e\n\u003cp\u003eLauren has interned for the Division of Enforcement and Division of Examinations at the U.S. Securities and Exchange Commission, the Money Laundering and Asset Recovery Section at the U.S. Department of Justice, the U.S. Attorney's Office for the District of Maryland, the Honorable Timothy J. Kelly, and the Office of General Counsel at\u0026nbsp;the National Archives and Records Administration.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9977}]},"capability_group_id":2},"created_at":"2025-09-02T04:54:31.000Z","updated_at":"2025-09-02T04:54:31.000Z","searchable_text":"Konczos{{ FIELD }}Lauren's practice focuses on securities enforcement, anti-corruption investigations, internal investigations, compliance counseling, white-collar criminal defense, and related civil litigation. Lauren represents clients before the U.S. Securities and Exchange Commission and U.S. Department of Justice, as well as other domestic and international authorities.\nLauren graduated from the Georgetown University Law Center and earned her M.A. and B.A. from the George Washington University. During law school, she was a Managing Editor for the American Criminal Law Review, a member of the Appellate Advocacy Division of Barristers' Council, and a student attorney for the International Women's Human Rights Clinic.\nLauren has interned for the Division of Enforcement and Division of Examinations at the U.S. Securities and Exchange Commission, the Money Laundering and Asset Recovery Section at the U.S. Department of Justice, the U.S. Attorney's Office for the District of Maryland, the Honorable Timothy J. Kelly, and the Office of General Counsel at the National Archives and Records Administration. Associate George Washington University  George Washington University  Georgetown University Georgetown University Law Center George Washington University  District of Columbia Women's White Collar Defense Association Intern, The Honorable Timothy J. Kelly, U.S. District Court for the District of Columbia","searchable_name":"Lauren O. Konczos","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":436614,"version":1,"owner_type":"Person","owner_id":193,"payload":{"bio":"\u003cp\u003eAllison Kassir develops and implements legislative and executive branch strategies related to health care, energy, and national security.\u0026nbsp; She has particular expertise in creating and representing new coalitions on targeted policy issues.\u0026nbsp; Allison also works as part of the firm\u0026rsquo;s congressional investigations practice. Allison was a recipient of\u0026nbsp;\u003cem\u003eNILE\u003c/em\u003e's \"Top Lobbyist\" award and \u003cem\u003eThe Hill\u003c/em\u003e's \"Top Lobbyist\"\u0026nbsp;award in 2023 and 2024.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAllison served in a variety of positions on Capitol Hill, including as a senior policy advisor to a Member of Congress and as part of the Member Services Team of the House Armed Services Committee.\u0026nbsp; She also served as a\u0026nbsp;special assistant to the Secretary of Defense.\u0026nbsp;\u003c/p\u003e","slug":"allison-kassir","email":"akassir@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":687,"guid":"687.smart_tags","index":0,"source":"smartTags"},{"id":23,"guid":"23.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":109,"guid":"109.capabilities","index":4,"source":"capabilities"},{"id":114,"guid":"114.capabilities","index":5,"source":"capabilities"},{"id":120,"guid":"120.capabilities","index":6,"source":"capabilities"},{"id":1184,"guid":"1184.smart_tags","index":7,"source":"smartTags"},{"id":124,"guid":"124.capabilities","index":8,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":9,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":10,"source":"smartTags"},{"id":1261,"guid":"1261.smart_tags","index":11,"source":"smartTags"}],"is_active":true,"last_name":"Kassir","nick_name":"Allison","clerkships":[],"first_name":"Allison","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"F.","name_suffix":"","recognitions":[{"title":"Top Lobbyist Recipient","detail":"The Hill, 2023-2024"},{"title":"Top Lobbyist Recipient","detail":"NILE, 2023-2024"}],"linked_in_url":null,"seodescription":null,"primary_title_id":78,"translated_fields":{"en":{"bio":"\u003cp\u003eAllison Kassir develops and implements legislative and executive branch strategies related to health care, energy, and national security.\u0026nbsp; She has particular expertise in creating and representing new coalitions on targeted policy issues.\u0026nbsp; Allison also works as part of the firm\u0026rsquo;s congressional investigations practice. Allison was a recipient of\u0026nbsp;\u003cem\u003eNILE\u003c/em\u003e's \"Top Lobbyist\" award and \u003cem\u003eThe Hill\u003c/em\u003e's \"Top Lobbyist\"\u0026nbsp;award in 2023 and 2024.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAllison served in a variety of positions on Capitol Hill, including as a senior policy advisor to a Member of Congress and as part of the Member Services Team of the House Armed Services Committee.\u0026nbsp; She also served as a\u0026nbsp;special assistant to the Secretary of Defense.\u0026nbsp;\u003c/p\u003e","recognitions":[{"title":"Top Lobbyist Recipient","detail":"The Hill, 2023-2024"},{"title":"Top Lobbyist Recipient","detail":"NILE, 2023-2024"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4349}]},"capability_group_id":2},"created_at":"2025-09-02T16:22:47.000Z","updated_at":"2025-09-02T16:22:47.000Z","searchable_text":"Kassir{{ FIELD }}{:title=\u0026gt;\"Top Lobbyist Recipient\", :detail=\u0026gt;\"The Hill, 2023-2024\"}{{ FIELD }}{:title=\u0026gt;\"Top Lobbyist Recipient\", :detail=\u0026gt;\"NILE, 2023-2024\"}{{ FIELD }}Allison Kassir develops and implements legislative and executive branch strategies related to health care, energy, and national security.  She has particular expertise in creating and representing new coalitions on targeted policy issues.  Allison also works as part of the firm’s congressional investigations practice. Allison was a recipient of NILE's \"Top Lobbyist\" award and The Hill's \"Top Lobbyist\" award in 2023 and 2024. \nAllison served in a variety of positions on Capitol Hill, including as a senior policy advisor to a Member of Congress and as part of the Member Services Team of the House Armed Services Committee.  She also served as a special assistant to the Secretary of Defense.  Senior Government Relations Advisor Top Lobbyist Recipient The Hill, 2023-2024 Top Lobbyist Recipient NILE, 2023-2024","searchable_name":"Allison F. Kassir","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}